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Despite successes in animals, cytokine gene expression selectively in human tumors is
difficult to achieve due to lack of efficient delivery methods.  We previously demonstrated that
adoptively transferred, IL-2 activated natural killer (A-NK) cells are very effective in trafficking
to, infiltrating and, subsequently, reducing B16 lung tumors in tumor-bearing animals.  We
therefore speculated that the tumor-seeking A-NK cells could be used for the delivery of
cytokines selectively to the tumor microenvironment.  However, tumor infiltration by A-NK
cells depends on high and often toxic doses of IL-2 to support the transferred A-NK cells’
survival and anti-tumor functions.  To address this problem, we hypothesized that A-NK cells
transduced to express pro-NK cell cytokines would become less dependent on high and
potentially toxic amounts of IL-2.  Assessments of transduction efficiency in vitro demonstrated
that adenoviral transduction consistently resulted in high (>60%) transduction rates and
substantial expression of transgenes such as GFP, luciferase, and mIL-12 for at least 4 days.  In
vivo experiments illustrated that mIL-12 transduced A-NK cells localized and survived
significantly better than mock transduced cells within lung metastases than in the surrounding
normal lung tissue when supported with low, non-toxic doses of IL-2.  The intratumoral survival
of non-transduced “bystander” A-NK cells also increased when they were co-injected with IL-12
gene-transduced A-NK cells.  The enhanced survival of exogenously delivered, IL-12 gene-
transduced A-NK cells resulted in greater anti-tumor responsiveness.  This led to a 7-10 day
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vincrease in median survival time compared to tumor-bearing mice receiving mock-transduced A-
NK cells.  These data show that the presence of IL-12 around tumor-infiltrating A-NK cells
enhances their anti-tumor activity while reducing their requirement for systemically administered
IL-2.  This A-NK cell delivered IL-12 has lead to an enhanced host anti-tumor reactivity, which
appeared to be mediated through cytokine involvement, namely IFNγ, rather than T, B, and NK
cellular activity.  Thus, adoptive transfer of A-NK cells represents an efficient method for
targeting products of genes to tumor sites and eliciting anti-tumor responses.
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11.0  INTRODUCTION
1.1 OVERVIEW
Despite the years of research dedicated to eradicating cancer, it has remained one of the greatest
killers in the United States.  The difficulty lies in not being able to always translate what works
in one person to others or all.  In addition to fine-tuning protocols such that they require great
specificity, such as with identifying and isolating tumor antigen specific T cells, it would be
more advantageous to focus on broader, more general approaches that can generate long term
individual specificities in their own capacity.
With continued research it is becoming clear that there are many issues that need to be
addressed before widespread success can be expected.  Tumors are apparently not considered
dangerous by the immune system, as in the case of an infection.  In many cases, tumors present
antigenic material that is self-derived and therefore not foreign to the host.  As a result, there is a
certain level of tolerance toward the tumor by the immune system.  It may be determined that
“danger” signals are necessary to activate and maintain the immune system against this
otherwise invisible threat.  On the other hand, the tumor may not be recognized by the host due
to the presence of immunosuppressive agents and regulatory cells within the tumor that could
counteract any potential anti-tumor host response.  Chemokines and anti-tumor cytokines may be
essential in overcoming the tumor’s evasive tactics by attracting immune cells to the tumor while
2maintaining their proper function, respectively.  The balance could be shifted, therefore, in favor
of host anti-tumor immunity and tumor destruction.
Having illustrated what could improve anti-tumor immune reactivity, there needs to be a
means to target and deliver these factors to tumors, including those in remote locations.  There
needs to be distinct specificity to limit the effects to the tumor and not surrounding normal
tissues, that could lead to unwanted systemic burdens.  IL-2 activated A-NK cells traffic to
remote tumors and accumulate to high numbers.  The potential of using these cells to act as
delivering vehicles is far reaching.  Non-protein based entities, such as viral or bacterial danger
signals, can be shuttled into A-NK cells successfully with peptide transduction domains (PTDs),
while proteins, including cytokines, chemokines, and prodrug activators, can be expressed
following viral transductions.  Furthermore, the combination of anti-tumor regulators is not
restricted to single candidates, as A-NK cells can express multiple viral genes simultaneously.
For the purposes of this dissertation, the focus will be on cytokine delivery to tumors by
administration of adenovirally transduced A-NK cells.  The cytokines chosen are due, primarily,
to their pro-NK qualities and, secondarily, their anti-tumor and host stimulatory capacity.
1.2 NATURAL KILLER CELLS
Natural killer (NK) cells have been extensively studied for their ability to defend against
pathogenic infections, to bridge innate immunity to adaptive responses, and mediate
immunosurveillance of cancers.  Comprising 5-15% of circulating lymphocytes, they are large
granular lymphocytes of the innate immune system.  Unlike T and B cells, NK cells generate
inflammatory responses without prior sensitization toward specific antigens, but rather
3coordinated stimulatory and inhibitory signals.  Once activated by pro-inflammatory cytokines,
NK cells exstravasate toward the site of infection to initiate an appropriate response.  This can
occur through the direct lysis of the target cells, occurring within hours to a day of infection,
rather than requiring several days to prime and/or accumulate to sufficient numbers to mount an
attack (as with B and T cells), or the release of cytokines and chemokines.
1.2.1 Natural killer cells in innate immunity
1.2.1.1 NK activation
The killing of target cells is a carefully balanced reaction in which normal cells are to be
spared while virally-infected and tumor transformed cells are lysed.  The surface phenotype of
NK cells contains both activating and inhibitory receptors (Figure 1).  Under normal conditions,
NK cells interact with MHC-I
expressed on other cells.  This
interaction overrides any killer
stimulating signals received
through activating receptor
engagement.  In mice, these
inhibitory receptors belong to
the Ly49 family while in
humans they include a family
of KIRs as well  as
CD94/NKG2A.  An ITIM motif
Figure 1. Control of NK-cell functions by the balance of
activation/inhibitory signals. Smyth, MJ et al. Nat Rev Cancer. 2002.
2(11): 850-61.
4in the cytoplasmic tail of these receptors inhibits further signaling, and ultimately killing
capacity.
When the expression of MHC-I is downregulated, in cases of viral infection, the
engagement of activating receptors is not inhibited leading to the lysis of target cells, in
accordance with the “missing self” hypothesis1, 2.  These receptors include the human natural
cytotoxicity receptors, NKp44, NKp46, and NKp30; mouse Ly49H and Ly49D; and NKG2D in
both humans as well as mice3.  In addition to cell-to-cell contact induced killing, NK cell-
mediated lysis can be triggered through antibody dependent cellular cytotoxicity (ADCC).  This
involves the FcγRIII, CD16, on NK cells interacting with antibodies bound to infected or
cancerous cells.
Apart from receptor/ligand communication, several cytokines/chemokines are integral in
triggering NK cell responses.  Type I interferons, IFNα/β, are produced early by virally infected
cells and have been shown to increase the trafficking4 and cytotoxicity5 of NK cells.  IFNα/β
may also have a proliferative effect on NK cells, as does IL-2 (discussed further below) and IL-
156.  IL-12 alone7(discussed further below) and in synergy with IFNγ, IL-1α/β, IL-18 or TNFα8,
9 activates NK cells, leading to the production of IFNγ.  Furthermore, MIP-1α/β and RANTES
are chemotactic for NK cells and may enhance their cytolytic function10, 11.
1.2.1.2 Cellular responses
Upon activation, NK cells respond with (1) granule exocytosis; (2) death receptor
mediated apoptosis; or (3) indirect killing through the release of cytokines or nitric oxide12.
Control of viral infections, including MCMV infection, can occur through lysis of infected cells
through the release of the pore-forming protein, perforin13.  The expression of TRAIL14 on the
5surface of NK cells promotes apoptotic cell death pathway.  Finally, NK cells influence immune
responses with the release of cytokines, such as IFNγ, TNFα and GM-CSF.  IFNγ, for instance,
is a potent cytokine, generated predominantly by NK cells in response to cytokine stimulation9,
15.  It aids in the protection against intracellular pathogenic infections13, 16, which may involve
hindering viral replication, inducing MHC molecule upregulation, and/or promoting T helper 1
(Th1) cell immunity.  The production of nitric oxide from the IFNγ-induced stimulation of NK
cells also contributes to innate immunity by activation of macrophages17.
1.2.2 Natural killer cells help bridge innate and adaptive immunity
Natural killer cells are involved in shaping adaptive immunity through various
mechanisms.  After NK cells are recruited to a site of injury they become partially activated in
response to cytokines such as type I interferons.  The NK cells become cytolytic against the
source of the threat, generating antigenic material for immature DCs (iDCs) to take up and
process.  DCs, in turn, produce pro-NK cytokines, such as IL-218 and IL-12, causing NK cells to
become more cytolytic and secrete IFNγ, and chemokines that draw more NK cells to the site19.
Activated NK cells may also begin to proliferate from the interaction with iDCs.  The production
of IFNγ and TNFα by activated NK cells, and cell-to-cell contact, further matures iDCs20-22.  The
“helper” function of NK cells requires two signals, where IL-2 or type I interferons must
accompany target recognition23.  If the ratio of NK cells to iDCs is high, iDCs are eliminated
through interaction with NKp30 on NK cells22.  However, in cases where the ratio of activated
NK cells to iDCs is low, DCs are matured.  As DCs mature their increased expression of MHC
inhibits lysis by NK cells22, 24.  Mature DCs (mDCs) then traffic to secondary lymphoid organs
6where they initiate adaptive responses with T cell sensitization due to increased MHC/antigen
(signal 1) and costimulatory (signal 2) expression by the mDCs.
NK cells can also directly affect the generation of cytotoxic T lymphocytes25.  This cell
contact dependent interaction, involving the expression of co-stimulatory molecules, such as
CD86 and OX40L, on the surface of NK cells, as demonstrated by Zingoni et al., can also
increase the proliferation and cytokine production of CD4+ T cells26.  The expression of CCR7
on a subset of human NK cells27 allows them to traffic to secondary lymphoid tissue where they
can influence T cell function, or through DC cross-talk.  IL-12-induced expression of IFNγ by
NK cells skews T cells toward Th1 immunity28.
1.2.3 Natural killer cells in cancer immunity
NK cells were discovered when it was found that there existed an inherent natural
reactivity towards cancer29-31 even when specific T cells were removed.  Their ability to provide
immunosurveillance against tumors was demonstrated with the clearance of tumor cells from the
circulation of mice32, 33 and rats34.  Later, it was shown that NK cells eliminate MHC I deficient
(“missing self”) tumors2.  NK cells have been investigated for their ability to protect against
spontaneous tumor formation and have been loosely correlated with better anti-tumor prognosis
when NK activity in patients is high35.  The ability of NK cells to mount immune responses
towards established, solid tumors in tissues has been more controversial.  The presence of NK
cells in various tissues36, however, as well as enhanced anti-tumor function with cytokine
activation37 points to their potential role in controlling against established tumors.  In addition,
increasing evidence from NK-depleted mouse experiments has demonstrated, on a number of
7occasions, that cytokine therapy is dependent upon NK cells for effective treatment of solid
tumors38-40.
In the same way NK cells control viral infections in innate immunity, they respond
against tumors with perforin release, apoptotic pathways, and cytokine secretion.  Perforin has
been established to mediate tumor cell lysis41, 42, involved in IL-12 activated killing of tumor
cells by NK cells43, and critical in the immunosurveillance against the formation of various
tumors44, 45.  The expression of FasL and TRAIL on the surface of NK cells promotes tumor cell
apoptosis46.  The apoptotic pathway is induced in many tumors upon engagement of TNF
receptors on the tumor cells47, to the point where NK cells have caused Fas expression by
tumors46. TNFα has also been shown to mediate rejection of tumors by NK cells48, while IFNγ
production by cytokine stimulated NK cells enhances CTL activity through induction of MHC
molecules on target cells and acts as an antiangiogenic agent49-51.
1.3 INTERLEUKIN-2
Interleukin (IL)-2 acts on a number of cells of the immune system.  It is a 15-kDa protein that
interacts with the IL-2 receptor made up of a β, γ, and α subunit.  The β and γ subunits make up
the intermediate affinity receptor, while upregulation of the α subunit (CD25) creates a high
affinity receptor.  The γ subunit is a common subunit shared by many cytokine receptors
including IL-7 and IL-15.  Upon receptor engagement, STAT5, in conjunction with JAK1 and
JAK3, is phosphorylated and transmigrates to the nucleus for increased survival and
proliferation.
81.3.1 IL-2 effects in immunology
1.3.1.1 Pro-inflammatory roles
IL-2 was originally discovered for its ability to proliferate T cells52.  The production of
IL-2, induced primarily in CD4+ T cells, occurs in lymphoid tissue following the co-stimulatory
signaling between CD28 on the T cells and B7 molecules (CD80 and CD86) on APCs53, in
conjunction with TCR engagement.  Without co-stimulation, therefore, the T cells do not
produce IL-2 sufficient to support expansion, even if they receive antigenic stimulation.
Activated effector CD8+ and Th1 CD4+ T cells secrete IL-2 promoting their own survival and
proliferation.  IL-2 also aids in the proliferation of B cells54, 55 and the activation of monocytes56
and neutrophils57.  The impact of IL-2 on NK cells has been shown to be important for their
growth and cytotoxic function58 and proliferation59.  IL-2 also contributes to NK functionality.
Cooper et al. have demonstrated a CD56hi subset of NK cells in humans that produces Th1
(IFNγ) and Th2 cytokines when stimulated by IL-260.  In addition to cytokine production, IL-2
has been shown to increase natural killer activity61.
1.3.1.2 Anti-inflammatory roles
Inasmuch as IL-2 is necessary for proliferative responses in activated effector and help T
cells, it is also critical in ensuring the cessation of such responses.  One way this is accomplished
is through CD4+CD25+ T regulatory cells.  IL-2 signaling allows for the development,
expansion and survival of CD4+CD25+ T cells62.  In addition, several studies have demonstrated
IL-2 to be essential for the functioning of T reg cells in establishing self-tolerance63, 64, with the
neutralization of IL-2 leading to autoimmunity from impaired T regulatory maintenance and
function65.  Furthermore, IL-2 affects the homeostatsis of CD8+ memory T cells by inhibiting
9their proliferation and accumulation66 through CD4+CD25+ T reg cells67.  Another means of
anti-inflammation is through activation-induced cell death (AICD)68, 69, where the direct
involvement of IL-2 has been shown from experiments using IL-2-/- mice70.  Continued
stimulation by IL-2, along with antigen restimulation, increases the expression of FasL on
activated T cells while decreasing the expression of the inhibitor of apoptosis, FLIP, resulting in
greater apoptotic T cell death69.  IL-2 is integral, therefore, in maintaining peripheral tolerance
toward self-antigens through the inhibition and/or removal of autoreactive T cells by
CD4+CD25+ T regulatory cells and AICD.
1.3.2 IL-2 applications in cancer therapy
Since its discovery as a potent proliferative agent for T cells, IL-2 has been the most
widely used cytokine adjuvant in cancer therapy.  The treatment of renal cancer is difficult and
has been unsuccessful with standard therapies, including chemotherapy.  Pioneering work by
Rosenberg et al. demonstrated, in a number of clinical trials involving patients with renal cell
carcinoma, considerable efficacy using high-dose IL-2 with a response rate around 20-30%71.  A
lack of noticeable responses from the addition of lymphokine activated killer (LAK) cells72;
application of low-dose IL-2, or coinjection of IFNα73, 74 has further confirmed the superiority of
high-dose IL-2 regimen.  High-dose IL-2 has also been used as therapy of melanoma.  Similar to
renal cancer, initial studies demonstrated IL-2 to be effective in treatment of advanced melanoma
when used alone75.
Although results vary, the use of IL-2 lymphokine activated killer (LAK) cells76, 77 has
been increasingly studied, from enhanced proliferation and killing capacity through IL-2
signaling.  More specifically, the identification and use of tumor specific T cells78 and tumor
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infiltrating lymphocytes (TIL)79-81 has resulted in a considerable response rate.  This response
from TILs was actually twice that seen with IL-2 alone82.  Immunotherapy involving IL-2 has
also benefited from the application of activated natural killer (A-NK) cells (discussed further
below)37, 83.  Finally, IL-2 in conjunction with various cytokines, such as IL-1284, IL-18 85, 86, and
IFNγ87, established IL-2 as a model cytokine in tumor immunotherapy.
IL-2 does not come without its drawbacks.  The toxicity generated from high dose IL-2
treatments has limited its application.  This can manifest itself in “capillary leak syndrome” in
which there is an increased movement of inflammatory proteins and activated lymphocytes
towards the interstitial spaces80, 88.  Although these issues have been reversible, there have been
complications less manageable, especially regarding the heart.  The toxicity of IL-2 is further
compounded when combined with other cytokines, such as IL-1289.  The benefits of joint
cytokine therapy, especially involving IL-2, need to be carefully monitored to offset the concerns
of toxicity.
1.4 INTERLEUKIN-12
Interleukin-(IL) 12 is a pleiotropic cytokine involved in many inflammatory responses.  It was
first identified for its ability to act as a natural killer stimulating factor (NKSF)7, giving its name
originally.  It consists of two covalently linked subunits, a p40 and a p35 subunit, making up a
70kDa protein.  Signaling through the β1 and β 2 subunit, IL-12 receptor, expressed
predominantly on NK and T cell, functions through STAT3 and STAT490.
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1.4.1 IL-12 effects in immunology
1.4.1.1 Innate immunity
IL-12 is produced by APCs, neutrophils, and B cells following interactions with
infectious particles or receptors on activated T cells (Figure 2)91.  Acting as a chemotactic
factor92, IL-12 can draw NK cells to the site of infection and then lead to an increase in cytolytic
activity and proliferation93.  NK cell proliferation seems to occur when IL-2 amounts are low,
possibly due to increased IL-2 receptor expression from IL-12 stimulation94, 95.  IFNγ is produced
in high levels by NK cells96 following IL-12 stimulation.  The IFNγ enhances MHC class I
expression and antigen presentation on DCs97 and T cell mediated immunity through T helper
cell activation98.  IL-12 also stimulates NK cells94, as well as neutrophils, DCs, and B cells, to
produce TNFα, IL-6, and IL-18, among others.  IL-12 induced TNFα and IL-6 production has
been shown to cause DCs to move to secondary lymphoid tissues where they interact with T
helper cells99.  A more direct effect of IL-12 on DCs is their maturation and enhanced antigen
presentation100, through MHC class II upregulation101.  Each of these direct or indirect activities
of IL-12 signaling on innate immunity, therefore, contributes to the initiation of adaptive
immunity.
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1.4.1.2 Adaptive immunity
IL-12 acts on naïve CD4+ T cells to differentiate them into Th1 cells98, 102, 103.  It
increases their proliferation along with generating a more activated phenotype with
proinflammatory cytokine production104.  Th1 cells express both subunits of the IL-12 receptor
whereas Th2 cells lose the β2 subunit, making them unresponsive to IL-12.  IL-12 enhances the
presence of Th1 cells at the site of its production by maintaining the Th1 cells.  This is
accomplished with an increase in chemokine receptor (CCR1) and integrin expression,
respectively.  Following IL-12 stimulation of various cell types, the chemokine IP-10 is
induced105 which can mediate further Th1 cell homing through their selective expression of the
Figure 2. Summary of the biology of IL-12. Trinchieri, G.  Nat Rev
Immunol. 2003. 3:133-46.
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IP-10 receptor, CXCR3.  As DCs interact with CD4+ T cells to prime efficient CD8+ cytotoxic
T lymphocytes (CTL), their production of IL-12 is critical for this process.  This is seen with
increased differentiation of CTL, in addition to their cytolytic capabilities105-108.  In fact, it has
been demonstrated that IL-12, along with antigen, can directly expand and differentiate naïve
CD8+ T cells109 and may play a role in the generation of immunological memory110.  Finally, IL-
12 has also been shown to play a role in B cell differentiation111 and in promoting Th1-associated
antibodies like IgG2a directly112, or via IFNγ113, or increased production of antibodies in
general114.
1.4.2 IL-12 applications in cancer therapy
The anti-tumor capacity of IL-12 has been overwhelmingly studied.  IL-12 has been
shown to augment the in vitro anti-tumor functions of NK cells, against hematologic and solid
malignancy115, and TILs, toward melanoma and ovarian cancer116.  In mouse studies, IL-12
promotes tumor regression, e.g. against melanoma, kidney and lung cancer when it is delivered
systemically, alone117-120 or in conjunction with peptide vaccination121 and DC vaccinations122.
Unlike IL-2, IL-12 has proven to be less toxic in treatment efficacy117, but not completely
without toxic effects123.  Further studies have been conducted to establish local delivery of IL-12
to a tumor, most prominently with the gene transduction of tumor cells.  This has included breast
cancer124, lung cancer125, and melanoma126, 127; DCs128, 129; and fibroblasts130, 131.  The anti-tumor
effects of IL-12, through these various delivery methods, have been shown to be mediated
through CD4+ T cells, CD8+ CTLs119 and NK cells43, leading to antigen specific immunity;
memory recall upon rechallenges and prolonged survival of tumor-bearing mice132.  As described
above, IFNγ is a major down-stream product of IL-12 signaling and therefore has been shown to
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contribute to IL-12 anti-tumor functions.  When IFNγ is neutralized, IL-12 efficacy is
abrogated119, possibly through decreased immune activity117 or inhibition of angiogenesis133, 134.
Although less well supported, there have been a few clinical studies with the
administration of IL-12.  Melanoma patients receiving peptide vaccine and IL-12 demonstrated
greater specific CD8+ T cell responsiveness, with regression of metastatic tumors, than if IL-12
is not given135.  Other studies have seen the generation of tumor specific CTLs with protein IL-
12136 and varied clinical responses from IL-12 transduced tumor cell137 and fibroblast138
therapies.
1.5 TUMOR IMMUNOTHERAPY
In order to initiate effective responses against a tumor, there needs to be the involvement of a
well-balanced immune system.  When deficiencies exist within the host, intervention must be
taken.  This can be accomplished through immunostimulation and active or passive
immunizations.  With active immunization, the goal is to stimulate the endogenous immune
system to generate specific immunity against the tumor.  Passive immunization, however,
involves the delivery of ex vivo-conditioned, activated cells capable of mounting anti-tumor
responses without additional support from the host.
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1.5.1 Active immunization
1.5.1.1 Cellular vaccines
DCs, presenting various tumor antigens, have been widely used to initiate host
responsiveness toward tumors in mice139-142 and, to a lesser extent, in clinical trials143, 144.  As
discussed above, the DCs can be gene modified to express cytokines.  Their success, and
alternatively their failure, has been shown to be dependent on the protocol used to mature the
DCs, selecting of tumor antigens, and the delivery route and frequency of DC injection145.
Maturation protocols have involved using a “cytokine cocktail” of TNFα, IL-1β, IL-6 and
PGE2146 or, more recently, a “megacytokine cocktail” of TNFα, IL-1β, PolyI:C, IFNα, and
IFNγ147.  This latter protocol allows for more potent CTL responses.  Additionally, DCs can be
matured in situ when antigen loaded immature DCs are injected into hosts pretreated with
adjuvant148.  Choosing the appropriate antigens to be loaded onto DCs to prevent autoimmunity
presents more complexity.  A further concern with this mode of tumor therapy involves very
insufficient trafficking of DCs to lymph nodes once they have been injected145 (most often
subcutaneously)149.
1.5.1.2 Non-cellular vaccines
The use of non-cellular vaccines has involved the application of tumor peptides.  The
identification of tumor-associated peptides has lead to their direct use in tumor therapy.
Although anti-tumor results have been attained in mice150, direct injection of single peptides with
complete or incomplete Freund’s adjuvant has been relatively ineffective, but not conclusive in
ruling out all immunostimulatory signals.  Ultimately, multiple peptides and danger signals could
serve as better vaccine modalities151.  Peptide vaccination with adjuvant and/or cytokine,
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predominantly IL-2, IL-12136 or GM-CSF152, has generated tumor antigen specific CTL
responses in patients with reactivity against melanoma, as well as cancers of the colon, ovary,
and breast.  The overall clinical responses, however, have been limited, even when DCs were
first pulsed with peptides ex vivo151.
Another technique for initiating host immunity has been the administration of
immunostimulatory agents.  IL-2 and IL-12, as discussed above, have been used in clinical trials.
In similar fashion, other cytokines have been incorporated into pre-clinical and clinical trials153.
IFNα, for example, has been systemically administered in the treatment of melanoma.
Kirkwood et al. have shown an increased survival following tumor resection in melanoma
patients receiving IFNα154.  Systemic delivery of GM-CSF has also generated therapeutic
results155, 156.  Local presence of cytokines within the tumor has become a more appealing and
effective approach in anti-tumor therapy.  It has become evident that not only the more
prominent candidate cytokines (IL-2, IL-12, and GM-CSF), but also Th2 cytokines, like IL-4 and
IL-6, have proven effective in tumor therapy.  This has been accomplished through intratumoral
cytokine injection, intratumoral injection of cytokine-gene containing viruses, and ex vivo
transduction of tumor cells153.  Although each method can be effective, by and large, systemic
cytokine strategies have not gained much ground, due to greater concerns from toxicity, while
local presence relies on tumors being accessible for direct injection reducing their applicability
for hard to reach tumors.
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1.5.2 Passive immunization
1.5.2.1  T cell adoptive therapy
With the development of efficient methods for culturing and propagating tumor antigen
specific T cells there has been increasing interest in using them in adoptive immunotherapy.
CD8+ T cells stand as the prime candidate for cellular adoptive therapy in that they possess a
distinct tumor specificity through their TCR with the potential of establishing long term memory,
persisting for a long time within the host, and being genetically altered.  Isolated from blood,
tumors (TILs), or draining lymph nodes, tumor reactive T cells have been identified with
specificity against overexpressed or mutated self-antigens that act as tumor-associated antigens
(TAAs) including MUC-1, MAGE, and MART-1.  Once identified, the T cells are expanded to
sufficient numbers to overcome the tumor burden157.  Basic ex vivo T cell stimulation protocols
involve the use of anti-CD3 antibodies and IL-2 to induce clonal expansion158, 159.  Additionally,
irradiated peripheral blood mononuclear cells, or feeder cells, serve to present antigen.  The cells
are then reinfused back into the patient along with IL-2 coadminstration (as described above).
There are certain concerns attached to T cell adoptive therapy, however, that has lead to
greater attention in their implementation.  For one thing, advances in animal studies have not
correlated as easily in clinical trials due to variability between antigens and greater self-tolerance
in humans.  The availability of vital cytokines in vivo can be competed out with the presence of
other immune cells.  The creation of this “cytokine sink” makes it difficult to amplify the anti-
tumor responses when cytokines, such as IL-7 and IL-15, are consumed by endogenous,
primarily NK160, cells.  Just as IL-2 is essential to CTL function, Treg cells depend on it
heavily63, 161, resulting in the increase of Treg numbers in cancer patients treated with IL-2162.
Not only can they deplete cytokine resources, Treg cells are also potent inhibitors of CTL
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reactivity directly163, 164.  The differentiation stage of the T cell also affects their ability to
respond appropriately165, seen in mice166 as well as humans167.  Traditional CD3/IL-2 protocol
for T cell transfer therapy may actually be detrimental to T cell function in that it may push them
to a late effector stage ex vivo, making them proliferatively exhausted, prone to apoptosis and
less responsive to cytokines than early stage effectors168.
To circumvent some of these issues, researchers have investigated new ex vivo T cell
protocols, genetic modification of the T cells, or host lymphodepletion.  Reducing the time – to
promote early effector cells169 – and/or changing the cytokine cocktails, e.g. to include IL-15170,
in which T cells are expanded may enhance the efficacy of the CTLs.  In addition to
costimulatory molecules and cytokines, naïve tumor specific T cells, which normally express low
affinity TCRs, have been transduced to express high affinity forms of these receptors171, 172,
making them more suitable for adoptive therapy.  Finally, lymphodepletion removes cytokine
competing cells from the host, especially Treg cells168, 170.  It has been proposed that with the
removal of host lymphocytes the body will try to maintain homeostasis by generating pro-
lymphocytic cytokines.  This cytokine storm can then benefit adoptively transferred cells in their
survival and expansion.
1.5.2.2 A-NK cell therapy
It was found that lymphokine activated killer (LAK) cells could be isolated from bulk
murine lymphoid preparations by their ability to adhere to plastic when cultured in the presence
of IL-2173.  They could then be further expanded with repeated passage of non-adherent cells
onto new plastic.  More importantly, as described above, LAK cells have been extensively used
in cancer immunotherapy in pioneering work by Rosenberg et al.  Their application, however,
has been limited by their need for high, and ultimately toxic, doses of IL-2.  It was later
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determined that these IL-2 activated, plastic adherent cells (A-LAK), were predominantly
comprised of activated natural killer (A-NK) cells, confirmed with negative staining for CD8,
CD4, and CD3 and positive for the NK markers, asGM1 and NK1.1.  A-NK cells once activated
with IL-2 remain dependent upon it for their survival, proliferation and cytotoxic function58, 61.
Adoptively transferred A-NK cells are capable of trafficking to established tumors.
Within hours of intravenous injection into tumor-bearing mice A-NK cells localize within tumor
nodules of different origins preferentially over normal lung tissue174.  The A-NK cells
accumulate in numbers over time.  As evidenced in vivo, IL-2 plays a key role in this process.
When no IL-2 is provided, A-NK cells cannot be found infiltrating lung tumors.  A constant
presence of IL-2, whether it be in the form of recombinant IL-2 given in 4-hour intervals or the
more efficient, polyethylene glycol conjugated form (PEG-IL-2) with a longer half-life, provides
for significant infiltration and accumulation of A-NK cells but does not depend on how the IL-2
is given175.  The route of administration of IL-2 bears little significance compared to that of the
A-NK cells which has proven to be crucial for selective trafficking to tumors, as systemic
injection resulted in substantial numbers of A-NK cells in lung tumors but fewer cells being seen
in extrapulmonary tumors, such as liver metastases.  Direct injection into the portal vein,
however, lead to a persistent presence of A-NK cells in the liver and liver metastases176, 177.
 Basse et al. further demonstrated the ability of A-NK cells to develop direct cell-to-cell
contact with melanoma tumor cells in the lung178.  As A-NK cells infiltrate tumors, this
correlates well with anti-tumor reactivity, with numbers reaching levels greater than 1000/mm2
of tumor tissue (Figure 3).  Yang et al. demonstrated that tumors infiltrated by A-NK cells to
such an extent can result in a 75-85% reduction in tumor burden compared to controls, in B16
and 3LL tumor models, as early as 120 hours after adoptive transfer.  Generating these results
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required 2 to 3 days of PEG-IL-2
support at 12-hour intervals83.  The
toxic nature of high dose IL-2,
however, remains a major issue for
the overall effectiveness of this
therapy.  If A-NK cells could be
manipulated to express IL-2 and/or
other cytokines many of the
problems mentioned above could
be addressed.  This would provide
an effective means to target
specific cytokine therapy to remote
tumors, supporting the A-NK cells
and host immunity, without toxicity or compromising their efficacy or having to identify tumor
antigens.
Figure 3.  A-NK cell infiltration of B16 tumor metastases.
Fluorescence/DIC image of lung tissue from animal treated with
20x106 A-NK cells 24 hours earlier.  The adoptively transferred A-
NK cells are visualized by immunostaining with PE-conjugated anti-
Thy1.1 antibody.  Scale bar = 100µm.
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SCOPE OF THIS THESIS
We set out to take advantage of the tumor-seeking nature of A-NK cells by cytokine-gene
transducing them, such that they would maintain their own support within tumors, and,
ultimately, create an environment that would promote further anti-tumor responsiveness.
Reducing systemic cytokine toxicity, targeting tumors more effectively, and broad tumor
specificity are critical issues that can be addressed using this technique.  It should be noted that
although we worked with transduced T-LAK cells (i.e., polyclonally activated CD8 cells) with
noticeable success (Chapter 2), A-NK cells were the major focus of this thesis.
In chapter 2, we demonstrate successful production of various genes through adenoviral
transduction.  Production levels were high in vitro and correlated well in vivo.  This was seen
with greater survival of A-NK cells within B16 tumor nodules if they had been transduced to
express IL-12 before adoptive transfer compared to no transduction.  The increase in A-NK cell
survival allowed for a prolongation in survival of tumor-bearing mice.
Next, we investigated further the functionality of IL-12-transduced A-NK cells.  By
transducing A-NK cells with IL-12 we have been able to reduce the amount of exogenous IL-2
administered without compromising their tumor trafficking and subsequent killing.  Survival of
mice (bearing lung tumors of different origin and age) was significantly greater in those
receiving A-NK cells transduced with Ad-IL-12 cells than Ad-mock or mice receiving high dose
IL-2 regimen.  The latter is not surprising considering the toxic effects of continued IL-2 support.
Finally, we set out to investigate the mechanistic aspect of the A-NK12 cell therapy and
the role of the host in the above studies.  Through the use of NOD-SCID mice we found that
increased survival of tumor-bearing mice receiving A-NK12 cells was likely not the result of host
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T, B, or NK cell function.  Despite the inability to significantly increase survival of tumor-
bearing mice, the addition of TNFα to A-NK12 cell treatment was able to improve the presence
of A-NK cells in tumors, while maintaining low exogenous IL-2 support.  In other experiments,
however, we discovered a role of the host through its production of IFNγ.  When recipients of A-
NK12 cells failed to produce IFNγ, they survived a significantly shorter amount of time.
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2.0  TARGETING OF PRODUCTS OF GENES TO TUMOR SITES USING
ADOPTIVELY TRANSFERRED A-NK AND T-LAK CELLS1
2.1 INTRODUCTION
Therapy of cancer involving cytokine genes is a new approach that has already shown promising
results, especially in animal models.  For example, ex vivo incorporation of a retroviral vector
expressing IL-15 into colon carcinoma cells179 or IL-18 cDNA into B16 cells127 inhibited tumor
growth in vivo following inoculation, and resulted in development of protective, systemic
immunity against the tumors.  In addition, IL-12 transduced tumor cells were not only capable of
generating local but also systemic anti-tumor responses when intratumorally injected along with
IL-15 protein126.   IL-2 transduced colon carcinoma cells induced both specific and non-specific
anti-tumor immune responses depending on the amount of IL-2 produced180.  While these studies
clearly demonstrate the very potent anti-tumor effects of intratumoral cytokine expression,
difficulties targeting the cytokine gene expression selectively to tumors remain a major limitation
of this therapeutic modality.  In those few, select cases where the tumor is accessible, direct
injection gene-therapy strategies have been widely explored and demonstrated a high degree of
success.  For example, when intratumorally injected as viral vectors containing the genes for IL-
2, IL-18, or IFNγ retarded the growth of subcutaneous tumors and prolonged survival40, 181, 182.
                                                 
1 Chapter 2 has been published in Cancer Gene Therapy. (2007.  14:441-450.)
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As an alternative to injection of viral vectors directly into tumors, several groups have injected
non-transformed cells, such as fibroblasts, transduced with cytokine genes into established
tumors.  Bubenik et al. injected IL-2 gene transfected fibroblasts peritumorally into nude mice
and found a growth inhibition of human carcinoma cell tumor xenografts183.  Likewise, Duda et
al. demonstrated an inhibition of colon carcinoma growth when tumor cells were co-injected s.c.
with IL-12 transduced 3T3 fibroblasts133.  Cytokine gene delivery directly to tumors has also
been achieved by employing cationic liposomes.  Ryuke et al. demonstrated a greater reduction
in subcutaneous melanoma lesions when IFNβ plasmids, complexed to liposomes, were
intratumorally injected as compared to recombinant IFNβ alone.  The anti tumor effect appeared
to be dependent on the presence of NK cells39.
Although fibroblasts are easily transduced with a number of viral vectors, using
transduced anti-tumor immune cells instead of fibroblasts provides an effector cell capable of
responding directly to the cytokines they themselves deliver.  In this scenario, anti-tumor
responses may be generated by the expressed cytokines via both the delivery vehicle and the
endogenous immune cells, enhancing the overall response.  For example, Nishioka et al. have
shown reduction in tumor burden following intratumoral injection of dendritic cells retrovirally
transduced to express IL-12128.  DCs, adenovirally transfected to express IL-12, have also been
shown to reduce colon adenocarcinoma metastases in the liver and elicit systemic anti-tumor
responses when injected intraportally129.
In the majority of cases, though, tumors are disseminated and cannot all be reached by
direct injection.  Thus, in order to selectively target the tumor, antibody-cytokine fusion
proteins184 and modified adenoviruses185 have been tested.  Antibody-IL-12 together with
antibody-TNFα fusion proteins were effective at eliminating small subcutaneous tumors but did
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not completely protect against rechallenge184.  Bauerschmitz et al. showed that modified
adenovirus was more efficient than native virus at impeding growth of tumors185.  Additionally,
Sakurai et al. showed systemic, i.v. delivery of IFNβ  or IFNγ lipoplexes to be effective
prophylactically as well as therapeutically against colon carcinoma lung metastases186.
However, it was found that empty lipoplexes performed nearly as well as IFNγ lipoplexes on
many counts.  Thus, despite the numerous methods developed for delivering cytokines or
cytokine genes to tumors they still remain relatively ineffective in their selectivity.
We have shown that lymphokine activated killer (LAK) cells, namely IL-2 activated
natural killer (A-NK) and IL-2 and PHA-activated T (T-LAK) cells, localize and accumulate
within lung tumor metastases when administered intravenously174, 187.  Based on their impressive
ability to accumulate selectively at tumor sites (regardless of the antigen expression by the
tumor), we hypothesize that A-NK or T-LAK cells transduced with cytokine genes may be used
as vehicles to target cytokines to sites of tumors.  This would, depending on the cytokine genes
employed, result in a local production of innate and adaptive immune regulators, thereby limiting
concerns as to their systemic availability, at the least, or toxicity, at the most.
Here we show that A-NK and T-LAK cells can be successfully transduced ex vivo with
adenoviral vectors to express a variety of products of genes such as eGFP, RFP, luciferase, and,
as an example of a pro-inflammatory cytokine, murine IL-12.  Furthermore, adoptively
transferred, adenovirally-transduced A-NK cells were found in 5-fold or higher density within
B16 melanoma and 3LL tumors than in normal lung tissue after transfer into tumor-bearing
mice.  The A-NK cells expressed the gene product (eGFP) in the tumors for up to 72-96 hours
post-injection.  T-LAK cells, as well, were capable of expressing various genes selectively
within tumor metastases.  Most importantly, regarding cytokine delivery, mIL-12 transduced A-
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NK cells demonstrated greater survival and anti-tumor effectiveness compared to mock
transduced cells, at low doses of exogenous IL-2.  On this background, we suggest that
adenovirally transduced A-NK and T-LAK cells can be used for the selective delivery to tumors
of an array of cytokines as well as other transgenic products displaying anti-neoplastic effects.
2.2 MATERIALS AND METHODS
2.2.1 Animals, tumor cell lines, and viral vectors
C57BL/6 and B6.PL-Thy1a/CyJ mice were purchased from Jackson laboratories (Bar
Harbor, ME).  The animals were housed in a specific pathogen free facility and the University’s
IACUC authorized their use.  F10 B16 melanoma cells and the Lewis lung, 3LL (ATCC),
carcinoma cells, both syngeneic to C57BL/6 mice, were maintained in complete media (CM),
which is RPMI1640 medium (Life Technologies, Gaithersburg, MD) supplemented with 10%
heat inactivated FCS, 2mM glutamine, 0.8 g/L streptomycin, and 1.6 x 10
5
 U/L penicillin.
Adherent tumor cells were harvested with 0.02% EDTA and washed in RPMI medium.  The
recombinant adenoviral vectors used in this study were E1/E3 deleted replication-defective type
5 adenoviruses188 (obtained from the Preclinical Vector Core Facility, University of Pittsburgh).
The cDNA encoding either Lac Z, murine IL-12, eGFP, or luciferase was inserted into the E1
region with gene expression driven by the early promoter of the human cytomegalovirus (CMV).
High titer recombinant adenoviruses were generated as described previously189, by Cre-Lox
driven homologous recombination and permissive replication in CRE8 cells, a 293 cell line that
expresses Cre recombinase.  Viral titers were determined by optical density at 260 nm (OD260)
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where 1 OD unit = 10
12 
viral particles190.  Polylysine (pK7) and RGD-fiber-modified adenoviral
Lac Z vectors were gifts from Dr. Imre Kovesdi (GenVec, Rockville, MD)191.
2.2.2 A-NK cell preparations
A-NK cells were generated from congenic B6.PL- Thy1a/CyJ spleens as previously
described 83.  Briefly, spleens were asceptically obtained and a single cell suspension was
generated.  Red blood cells were lysed by incubating the splenocytes with red blood cell lysing
buffer (Sigma-Aldrich, St. Louis, MO) at 1ml/spleen for 2 minutes with swirling every 30
seconds.  Following filtration through a 70-µm filter, the remaining bulk splenocytes were plated
in culture flasks, maintained at 37
o
C and 5% CO2 in CM and 6,000 IU/ml human recombinant
IL-2 (kindly provided by the Chiron Corporation, Emeryville, CA).  Up to 72 hours after the start
of culture, non-adherent cells were passaged to new flasks while the adherent cells were given
fresh CM and IL-2 as needed, as described previously173.  These plastic-adherent, A-NK cells
were used on Day 5 or 6 of culture.  Routinely, these A-NK cells were >95% Thy1.1+, >95%
asGM1+, >90% NK1.1+, <2% CD8+, and <2% CD4+.
2.2.3 T-LAK cell preparations
Splenocytes were obtained as described above and transferred to T150 plastic flasks at 2
x 10
5
 cells/ml of complete medium.  The cells were activated with 600 IU/ml of rhIL-2 and 0.4
µg/ml of PHA-P (phytohemagglutinin-P; DIFCO, Detroit, MI, USA).  After 2 days of
incubation, clusters of T cells were transferred to 50 ml tubes and sediments were allowed to
form for 5-7 min. before the supernatant was gently removed.  The cell sediment was
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resuspended at 1 x 10
5
 cells/ml of fresh CM containing 600 IU IL-2/ml.  Three days later, the
cells were harvested, washed twice, and resuspended in RPMI-1640.  Routinely, the T-LAK cells
were found to be >95% Thy1, >95% asGM1+, >90% CD8 (Lyt-2)+, >90% CD3+, but <5%
NK1.1+, and <2% CD4 (L3T4)+, in agreement with previous findings187.
2.2.4 Viral transductions
A-NK or T-LAK cells were collected (A-NK cells with 0.02% EDTA), washed with CM,
and resuspended in RPMI without serum at a concentration of 10 x 10
6
 cells/ ml (or 40 x 10
6
cells/ml for in vivo studies).  Virus was added at various multiplicities of infection (MOIs) and
the cell suspensions were incubated at 37
o
C for 90-120 minutes.  During the incubation period
the tubes were gently shaken every 15 minutes.  The cell suspensions were then placed into
culture flasks containing CM and 6,000 or 600 IU/ml IL-2 for A-NK or T-LAK, respectively.
Cells were again incubated at 37
o
C for the indicated number of hours for each assay.  Before
each assay and the in vivo tumor experiments, cells were harvested and washed 3 times in a large
volume or in excess CM to remove unincorporated virus.
2.2.5 Flow cytometry
Adenovirally transduced A-NK cells were harvested, washed, and fixed in 0.25%
paraformaldehyde.  Samples were run on a Beckman Coulter Epic XL-MCL FACs machine,
collecting 5000 events.  Data obtained from histograms was compared to non-transduced control
groups.
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2.2.6 Luciferase, b-galactosidase, and cytokine production
The production of luciferase and β-galactosidase were assessed using substrates from
Luciferase Assay System (Promega, Madison, WI) and Galacto-Light Plus (Tropix, Bedford,
MA), respectively, according to the manufacturer’s protocol.  Samples were analyzed on an
Autolumat LB-953 luminometer (Berthold Technologies, Bad Wildbad, Germany).  Cytokine
production was measured using sandwich ELISAs on supernatants for murine IL-12p70 and
IFNγ (Endogen, Woburn, MA).
2.2.7 Adoptive transfer experiments
Lung tumor metastases were established by injecting B16 and 3LL tumor cells (4 x
10
5
/0.4 ml of RPMI) intravenously into C57BL/6 mice pretreated 24 hours earlier with an i.p.
injection of anti-asialo-GM1 antiserum (Wako PureChemicals, Wako, TX) at 25 µl in 0.5 ml
PBS.  Following 24 hours of in vitro culture, Ad-eGFP transduced A-NK cells were harvested
from flasks and washed.  Eight and twenty million cells/ 0.4 ml RPMI were injected i.v. into
mice with day-10 3LL and  B16 lung metastases, respectively.  The transferred A-NK cells were
supported by 0.5 ml i.p. injections containing 60,000 IU of IL-2 in complex with polyethylene
glycol (PEG-IL-2, a kind gift from the Chiron Corporation, Emeryville, CA), starting at 0 hours
and every 12 hours thereafter, up to 72 hours.  For the RFP-T-LAK experiment, B16 cells were
injected i.v. at 3.0 x 10
5
/0.3ml RPMI.  At day twelve of tumor growth, mice then received 22 x
10
6
 Ad-Red2 (RFP) transduced T-LAK cells in 0.4 ml RPMI.  Following the cellular transfer,
mice received 30,000 IU/ml PEG-IL-2 injections every 12 hours up to 48 hours post injection
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when all mice were sacrificed.  For experiments employing mIL-12 transduced A-NK cells, B16
lung tumor metastases were established with 3.0 x 10
5
 /0.4ml RPMI.  Three days later, 5.0 x 10
6
Ad-IL-12 or mock transduced A-NK cells were injected i.v. in 0.4 ml RPMI.  Injections of PEG-
IL-2, at 60,000 IU/ml, were given two times within 24 hours of the injection of the A-NK cells.
2.2.8 Estimation of adoptively-transferred A-NK and T-LAK cell infiltration of lung
metastases and survival analysis
Using the Thy1.1/1.2 congenic system the infiltration of the transferred A-NK cells was
determined as described previously83.  Briefly, one half of organ samples obtained from mice at
various time points were fresh frozen at –70
o
C.  Eight micron thick sections of the organs were
stained with PE-conjugated, anti-Thy1.1 Ab (Pharmingen) at a 1:200 dilution and compared to
PE-conjugated IgG2b Ab controls.  The other half of the organ samples were fixed in 1%
paraformaldehyde for 3 hours then 30% sucrose overnight.  These fixed tissues were then snap
frozen, sectioned, and GFP+ A-NK, or RFP+ T-LAK, cells were identified by fluorescence
microscopy.  Fluorescent and DIC images of the tissue sections were obtained using a Nikon
fluorescent microscope and analyzed for cell numbers using MetaMorph image analysis
software83.  Mice were code numbered and monitored for survivability by two observers with no
knowledge of the code.  When reaching a premorbid condition, as defined by our IACUC, mice
were sacrificed and the lungs were removed, dried and weighed (the average dry weight of the
lungs from the mock transduced A-NK and AdIL-12 transduced A-NK groups (Fig. 9) were
0.189g±0.01g versus 0.163g±0.03g, respectively, ensuring that the mice, at time of sacrifice, had
reached the same stage of tumor development).
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2.2.9 Statistical analysis
Two-tailed, unpaired student’s t-tests were performed with a 95% confidence interval.
For survivability curves, data were plotted according to the Kaplan-Meier method with statistical
significance determined using the log-rank test.
2.3 RESULTS
2.3.1 A-NK and T-LAK cell expression of the marker protein eGFP following adenoviral
transduction.
It was determined, first of all, to what extent the A-NK and T-LAK cells, capable of
localizing to tumors, were transducible with adenoviral vectors.  Since eGFP provides a quick
assessment of successful transduction, an adenoviral (serotype 5) vector with the gene for eGFP,
under the control of a CMV promoter, was chosen for this purpose.  Within 24 hours of virus
incubation, a considerable production of GFP was noticed by the A-NK and T-LAK cells
compared to non-transduced cells (Figure 4, A and A).  When high MOIs were used, the
presence of GFP was evident for up to 168 hours, but expression peaked around the 48-hour time
point, at which time the percentage of GFP positive A-NK cells reached levels of 70-80%
(Figure 4, A and B, 80 and 160 MOIs). In general, higher transduction rates were achieved with
A-NK cells than T-LAK cells (Fig. 4, A and B).  The production of GFP by the A-NK and T-
LAK cells was due to the original application of virus and not to viruses replicating in the A-NK
or T-LAK cells or from transfer of GFP from transduced to non-transduced cells in that no GFP
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positive cells were witnessed among non-transduced cells when these were co-cultured with cells
transduced 24-48 hours earlier (data not shown).
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Figure 4. Ad-eGFP transduction of murine A-NK or T-LAK cells.  5x106 A-NK (A) or T-LAK (B)
cells were transduced with Ad-eGFP at the indicated MOI and tested for GFP expression by flow cytometry.
Percentage GFP-positive cells were determined at five different times over the course of a week.  (C) The cell
numbers of transduced A-NK cells were calculated for extended growth of the 5x10
6
 cells originally plated.
A concern of viral transduction, especially at high MOIs, is that of toxicity to the
transduced cells.  The viability and proliferative capacity of A-NK and T-LAK cells transduced
A B
C
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at increasing MOIs was therefore examined.  Trypan blue dye exclusion tests revealed a high
viability of both A-NK cells and T-LAK cells at 24 hours at all MOIs tested, indicating a low
immediate toxicity of the virus (data not shown).  However, while analysis of cell growth one to
five days after transduction demonstrated that all cells continued to grow, it was clear that the
growth-rate of cells transduced at higher MOIs was somewhat suppressed - especially during the
first days after transduction - compared to non-transduced control cells and cells transduced at
lower MOIs (Fig. 4C).
2.3.2 Functional enzymes, luciferase and beta-galactosidase, are expressd by transduced
A-NK cells.
It was of critical importance to demonstrate that gene delivery and expression in A-NK
cells could result in production of proteins other than GFP.  Adenoviral vectors with the genes
for luciferase (Ad-luc) and beta-galactosidase (Ad-beta-gal), respectively, were therefore
employed.  After 48 hours of culture, lysates of Ad-luc transduced A-NK cells showed a marked
increase, more than 100-fold increase in light activity seen after the addition of D-luciferin
substrate as compared to non-transduced cells (Fig. 5A).  Likewise, cells transduced with Ad-
beta-gal reacted strongly when assayed with Galacto-Light Plus, a luminescent substrate system
(Fig. 5B).  Modified adenoviral vectors, such as Ad-RGD and –PK7 (Fig. 5B) enhance uptake
35
Luciferase production
0
1000
2000
3000
4000
5000
6000
7000
8000
0 MOI 200 MOI
RL
U/
s
          
Beta-galactosidase production
1
10
100
1000
10000
100000
1000000
10000000
Ad-LacZ-1 Ad-LacZ-2 Ad-LacZ-3
LacZ vector 
RL
U/
s
12.5 MOI
50 MOI
100 MOI
Figure 5. Ad-luc and Ad-LacZ transduction of murine A-NK cells. 2.5x10
6
 (A) or 1x10
6
 (B) A-NK
cells were transduced with the indicated MOI of Ad-luc or Ad-lacZ vectors and tested for luciferase expression
using the Luciferase Assay system or for β-galactosidase expression using the Galacto-Light Plus kit, respectively.
Ad-LacZ-1, -2, and -3 correspond to wild type Ad-LacZ, -PK7-LacZ, and -RGD-LacZ, respectively.  Samples were
assessed for both genes after 48 hours of virus culture.  Results are given as relative luminescent units/second
(RLU/s) run in triplicate.
through unconventional receptors, the integrin and heparan sulfate receptors, respectively.  Using
these vectors, we achieved a greater transduction efficiency and gene expression of the A-NK
cells compared to the unmodified Ad5 vector.  Taken together, these data demonstrate that in
addition to susceptibility to GFP gene-transduction, A-NK cells can be efficiently transduced to
express genes coding for various enzymes.
2.3.3 Transduced A-NK and T-LAK cells can produce a potent regulator of adaptive
immunity.
The next important step was to investigate whether A-NK and T-LAK cells could be
transduced to over-express cytokines involved in anti-tumor immune responses.  To test the
A B
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production of such an agent, an adenoviral vector expressing murine IL-12, a cytokine known for
its ability to stimulate NK and T cells192, 193 and to enhance CTL response and promote Th1
immunity103, 194, was employed.  As seen in Figure 6A, A-NK and T-LAK cells were
successfully transduced with the Ad-mIL-12 vector to secrete high amounts of mIL-12.  The
production of mIL-12 by transduced A-NK cells followed similar kinetics as the GFP
production, namely with a peak expression around the 48-hour time point (compare Fig. 4B with
Fig. 6B).  The functionality of the mIL-12 was confirmed by demonstration of an elevated IFNγ
production from the transduced A-NK and T-LAK cells compared to non-transduced cells
(Figure 6C).  The IFNγ production by T-LAK cells transduced with the mIL-12 gene was not
significantly different from that of A-NK cells despite their lower mIL-12 production.
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Figure 6. Primary IL-12 production and secondary IFNg production by Ad-mIL-12 transduced
murine A-NK and T-LAK cells.  3x10
6
 A-NK or T-LAK cells were transduced with the indicated MOI of Ad-
mIL12.  Cells were washed after 24 hours culture and given fresh media.  24 hours later, supernatants were collected
and analyzed for the presence IL-12 (A) or IFNγ (C). 25 MOI for T-LAK not tested (*).  (B) 2x10
6
 ANK cells were
transduced with the indicated MOI of Ad-mIL-12.  Supernatants were harvested at various times and assayed using
ELISA.  Values are given in pg/ml for the total amount of mIL-12 present in the culture flask by multiplying the
number of ml of supernatant by the ELISA readings for a 1/10 dilution of samples.
2.3.4 Selective tumor homing by adoptively transferred, A-NK and T-LAK cells
transduced with various genes.
Having demonstrated the success of A-NK and T-LAK cell adenoviral transduction, we
next studied the ability of the transduced cells to localize at tumor sites upon adoptive transfer
and to express the transgene while in the tumor tissue.  Mice were injected with 3LL or B16
tumor cells to induce pulmonary metastases and ten days later, 8 million Ad-eGFP transduced A-
NK cells were injected i.v.  Exogenous PEG-IL-2 injections were given every 12 hours to
support the transferred cells as previously described175.  At various times organs were harvested,
fixed, cryosectioned and analyzed for the presence of A-NK cells and GFP.  As early as 24 hours
after injection, the density of the transferred A-NK cells was, as expected, significantly higher in
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the tumor tissue compared to the normal lung tissue, and the A-NK cell density in the tumor
tissue continued to increase for the next 3 days (400±138, 750±104, 810±290, and 1179±174
cells/mm
2
 at 24, 48, 72, and 96 hours, respectively).  The expression of GFP in the tumor tissue
was also significantly higher in the tumor tissue than in the surrounding normal tissue from 24
hours and until 96 hours.  Figure 7 shows the presence of GFP expressing A-NK cells at 72
hours in lung 3LL (Fig. 7A) and in B16 (Fig. 7B) tumors.  As could be expected, though, based
on the loss of GFP expression from the cells from 72 hours after transduction (Fig. 4), expression
was maximal at 48 hours and declined thereafter (Fig. 7C) but remained significantly greater
within the tumor tissue compared to normal tissue at all times evaluated, p-value <0.05.  As seen
in Figure 7D, T-LAK cells transduced to express RFP were found at a ratio of 10:1 in tumor
tissue compared to normal lung tissue 48 hours after injection.  Thus, although less transducable
than A-NK cells, T-LAK cells may also serve to localize products of genes to tumor tissues.
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Figure 7. GFP or RFP expression within lung tumor metastases by adoptively transferred
transduced cells.  (A and B, respectively) 8 x 10
6
 or 20 x 10
6
 GFP-transduced A-NK cells were injected i.v. into 10-
day 3LL or B16 (black pigmented) tumor-bearing mice.  The 3LL tumor area (panel A) has been darkened for
visualization.  These panels illustrate lung tumor areas 72 hours post injection, infiltrated by A-NK cells capable of
expressing GFP (green dots).  Bars represent 100 microns. (C) Paraformaldehyde-fixed lung tumor sections were
analyzed for the expression of GFP both within tumor tissue as well as normal lung tissue. Using Metamorph
imaging software, the total number of pixels (corresponding to GFP expression) above background was measured.
Data are expressed as number of pixels per square mm. normal lung and tumor tissue (average of 3 animals per time
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point).  P-values were significant for each time point analyzed, with values <0.005 for 24, 48, and 72 hours and
<0.05 for 96 hours.  (D) A representative image of a 12-day B16 lung tumor (black pigmented) at 48 hours after
injection of 20 x 10
6
 Red2-(RFP) transduced T-LAK cells is depicted. Bar represents 100 microns.
We also analyzed liver and spleen tissue sections for the presence of transduced cells, to
rule out the possibility of non-specific targeting.  We found GFP expression in the liver, for
example, to be only 1.95% of that of lung tumors, with a similarly low density of Thy1.1 positive
cells.  The density of NK cells, as well as GFP expression, in other organs (such as kidneys and
spleen) appeared to be substantially lower than the GFP expression in liver.
To illustrate the benefit of expressing a cytokine selectively within lung tumors, A-NK
cells were transduced with Ad-mIL-12.  B16 tumor-bearing mice received 5 million Ad-mIL-12
or mock transduced ANK cells along with two injections of full dose of IL-2 (60,000 IU/ml)
only.  Cells were quantitated in lung tumor metastases 72 hours after adoptive transfer.  At this
time we discovered a substantially greater number of exogenous A-NK cells within lung tumors
when they were first ex vivo transduced to express mIL-12 (Fig. 8A) than if they had been mock
transduced (Fig. 8B).
A B
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Figure 8. Selective mIL-12 expression in lung metastases enhances cell survival. (A and B,
respectively) 5 x 10
6
 mIL-12 or mock transduced A-NK cells were injected i.v. into 3-day B16 tumor-bearing mice,
and supported with 2 injections of 60,000 IU/ml PEG IL-2. Fresh frozen lung tumor sections were analyzed for
surviving adoptively transferred cells at 72 hours post injection.  Representative images at this time point are given
for mIL-12 transduced (A) or mock transduced (B) A-NK cells in B16 lung tumor-bearing animal.  In both panels,
the adoptively transferred A-NK cells are depicted with PE-conjugated anti-Thy1.1 Ab at a 1:100 dilution.  Bars are
equal to 50 microns.
We also found a significant anti-tumor response, as determined by mouse survivability,
which accompanied the enhanced cellular survival of mIL-12 transduced cells.  We found that
mock transduced A-NK cells provided no benefit in mean survival of mice compared to that seen
with the exogenous IL-2 only treatment group (Fig. 9).  In contrast, mice receiving mIL-12
transduced A-NK cells survived significantly longer than Il-2 treated mice and mice treated with
Mock transduced cells (Fig. 9, 26 days compared to 16 days for mock transduced mice, p value
<0.005).  We, therefore, conclude that A-NK cells can be used to deliver transgenic products,
including pro-inflammatory cytokines such as IL-12, to sites of tumors to augment anti-tumor
responses.
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Figure 9. Selective mIL-12 expression in lung metastases provides for an overall greater survival in
mice.  Survival of mice (from Figure 8) was determined in a blinded fashion as described in Material and Methods
and plotted using the Kaplan-Meier method.  Log-rank test demonstrated a significant difference in survival time
between mice receiving IL-2 only or mock transduced A-NK cells and mIL-12 transduced A-NK cells (p
value<0.005, n=5).
2.4 DISCUSSION
Activation of macrophages involved in innate immunity, of dendritic cells in initiating adaptive
immunity, and of T cells providing effector function and memory all depend on cytokine
interactions.  Numerous studies describe how administration of cytokines43, 195 can help boost
these immune reactions.  For instance, Kodama et al. and Hashimoto et al. have demonstrated
that the administration of recombinant IL-12 or IL-18 resulted in a noticeable anti-tumor effect in
mice43, 195.  Furthermore, the effects of IL-18 together with IL-2 were greater than either cytokine
alone in reducing the number of lung metastases in mice85.  However, caution must be taken in
administering combinations of recombinant cytokines for therapeutic purposes, such as IL-2 and
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IL-1289 or IL-12 and IL-18196, or even IL-18 alone197, in that fatal toxicity may result.  There is a
fine balance, therefore, in ensuring that the amount of cytokine administered is sufficient to
activate and sustain the immune system, but not so elevated that treatment-limiting toxicity is
induced.  In order to reduce toxicity, it seems logical to directly target the cytokine(s) to sites of
established tumors.  While the application of fibroblasts transduced with cytokine genes has
delivered proof that selective presence of cytokine in tumors leads to tumor reduction with very
little or no toxicity, this approach is limited by the fact that the cells must be injected directly
into the tumors.  Viral vectors or liposome complexes, when injected intravenously, may be
mistargeted, degraded, or may never locate and infiltrate the actual tumor198.  Furthermore, along
with injection of recombinant cytokines, their systemic application may lead to development of
toxicity.  These, and other, shortcomings prompted us to investigate the use of lymphocytes
capable of localizing at tumor sites as delivery vehicles of products of genes, including
cytokines.  We focused on A-NK and T-LAK cells as vehicles for tumor-selective targeting of
transgenes, since we have previously demonstrated their ability to localize to remote,
disseminated lung tumor metastases.
It was important to demonstrate, first of all, that the A-NK and T-LAK cells could in fact
be successfully transduced with genes.  Second, we wanted to determine if A-NK and T-LAK
cells could express immunologically relevant genes, in particular those pertaining to cytokines.
Finally, we needed to illustrate that the transduced cells maintain the capacity to traffic to
tumors, without a loss in viability or ability to express the transgene.
For the gene transduction, we focused on adenoviral vectors since they were capable of
infecting A-NK and T-LAK cells at high rates, could be generated to high titers, and could
introduce genes of up to 8 kb into cells199.  In fact, transduction of A-NK and T-LAK cells with
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other types of vectors, e.g. retrovirus and lentivirus, resulted in very low transduction rates (0.1-
~10%).  Since A-NK and T-LAK cells divide for only a limited amount of time (2-4 weeks),
cloning of a relatively low number of successfully retro- and lenti-virally transduced A-NK/T-
LAK cells, therefore, was not feasible.  We show here that a variety of genes, such as GFP, RFP,
luciferase, as well as murine IL-12, could be successfully expressed by a high percentage of the
A-NK and T-LAK cells.  Judged by both GFP and mIL-12 expressions, the transduction
efficiency was high and expression persisted, although reduced considerably with time, to at
least a week after transduction.  Thus, A-NK cells that were greater than 80% GFP-positive at 48
hours after Ad-GFP transduction, fell below 30% GFP-positive cells by day 7.  This may be
explained by the fact that adenoviruses are unable to integrate their genetic material into the host
genome, and therefore incapable of replicating.  Thus, the originally delivered viral genes
became diluted with successive rounds of division of the rapidly proliferating A-NK and T-LAK
cells.  In addition, inactivation of the CMV promoter of the adenoviral vectors also contributes to
the declining gene expression200.
Somewhat surprisingly, T-LAK cells proved harder to transduce than A-NK cells.  While
up to 80% of the A-NK cells expressed eGFP at 24-48 hours after transduction, only about 30%
of the T-LAK cells, transduced under the same conditions, were eGFP+ at this time.  Whether
this results from a lower expression of coxsackie and adenovirus receptor (CAR) on the T-LAK
cells compared to A-NK cells is under investigation.  To improve the transduction rate of T-LAK
cells, it may be possible to employ fiber knob-modified or biotinylated adenoviral vectors201 that
can be taken up through various receptor interactions.  A preliminary experiment in our
laboratory indicates that DMRIE-C, a liposome-cholesterol reagent used to enhance DNA/RNA
and virus transfection202, 203, improved the T-LAK cell transduction rate.  It is also possible that
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other modified adenoviral vectors such as Ad-RGD and –PK7, which improved transduction of
A-NK cells, will also be able to improve the transduction efficacy of T-LAK cells.
We also tested the ability of adenovirally transduced A-NK and T-LAK cells to express
functional, anti-tumor cytokines.  Both cell types were transduced with an Ad-mIL-12 vector.
As early as 24 hours after transduction, both cell types produced significant amounts of mIL-12,
with A-NK cells producing greater amounts.  Again, the expression of this gene was evident for
more than 72 hours.  Also, the mIL-12, as well as mIL-18 (data not shown), gene transduction
led to the induction of secondary cytokine/chemokine production.  Levels of IFNγ, for example,
were markedly elevated in supernatants from A-NK and T-LAK cells transduced with mIL-12
(and mIL-18, data not shown) genes as compared to non or mock transduced cells.  In spite of
the low mIL-12 levels generated by transduced T-LAK cells, the levels of IFNγ generated by the
mIL-12 transduced T-LAK cells were equal to those generated by mIL-12 transduced A-NK
cells, as confirmed from separate experiments.  This is encouraging considering the significantly
greater amount of mIL-12 produced by A-NK cells compared to T-LAK cells.  Apparently, the
mIL-12 produced by the T-LAK cells is fully capable of boosting downstream immune
responsiveness as evidenced by the robust production of IFNγ.
Having demonstrated the efficiency of adenoviral vectors to transduce A-NK and T-LAK
cells, we tested whether this procedure would translate to selective targeting of gene expression
in our lung tumor model.  Although previous reports have indicated A-NK and T-LAK cells
possess the ability to home to and infiltrate lung metastases, we were uncertain of any deleterious
effects adenoviral transduction may have on this.  However, we did not find any indication of
negative effects of gene transduction on tumor localization since Ad-eGFP and Ad-Red2
transduced A-NK and T-LAK cells, respectively, localized to tumors to the same degree as non-
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transduced cells83, 204.  Thus, for both A-NK cells and T-LAK cells, increasing cell densities
within the metastases were found up to 96 hours.  Accordingly, the density of GFP-positive cells
also increased after injection, but, in contrast to the cell density, as measured by immunostaining,
measurable GFP declined after 48 hours.  We believe this is caused by both inactivation of the
CMV promoter and dilution (due to cell proliferation) of the transgene, as discussed above.
From these data, it is clear that adenoviral transduction of A-NK and T-LAK cells does not
hinder their ability to traffic to and infiltrate lung tumors.  In addition, the transduction process
does not appear to be toxic to the cells, but results in successful expression of the transgenes by
the tumor infiltrating A-NK and T-LAK cells.
The gradual loss of GFP or RFP signal due to dilution of the genetic material for each A-
NK and T-LAK cell division clearly reduces the usefulness of these fluorescence products as
markers for individual cells.  However, as long as all A-NK and T-LAK progeny remain at the
tumor site, one would expect that the overall gene expression would only become reduced due to
inactivation of the viral genes.  Thus, sufficient levels of pro-immune cytokine may be achieved
by the combined effort of many cells each producing a modest amount of cytokine.  Moreover,
the A-NK/T-LAK cells infiltrating the lung tumors are confined to an environment with very
little extracellular fluid.  Therefore, even the production of a numerically modest number of
cytokine molecules may result in cytokine-concentrations sufficient to stimulate both the
exogenously delivered and endogenous immune effector cells.  This cytokine benefit has been
clearly demonstrated from our results illustrating a substantially improved effector cell survival
and anti-tumor effect by mIL-12 gene transduced effector cells compared to mock transduced
cells.  It should be noted that the anti-tumor effect of the transduced cells was maintained even in
the presence of only two initial injections of exogenous IL-2 support, a key factor in eliminating
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systemic toxicity, which usually appears after two to three days of exogenous IL-2 treatment.
Although the treatment of mice receiving mIL-12 transduced cells did not result in complete
cure, these mice survived significantly longer compared to mock transduced cell recipient mice.
With repeated adoptive transfer or multiple/different cytokines (as in ongoing experiments), it is
imaginable that greater survival could be attained, ultimately leading to curative benefits.
All taken together, our data demonstrate the potential of A-NK and T-LAK cells to
deliver anti-tumor products of genes, including cytokines, directly to the site of tumor growth.
We envision that not only single cytokines, but also cytokine combinations, can be directed, at
various times and intervals, to tumor tissues by transduced A-NK and T-LAK cells to induce
strong and sustained anti-tumor immune responses.  By not being dependent on injection of the
genetic material directly into tumors, this technique can provide therapeutic benefit to multiple
and remote tumors.  In addition, achieving a selective, local production of cytokines should
eliminate, or greatly reduce, the toxicity associated with systemic cytokine administration, since
the cytokine effects will be concentrated right where they are needed, namely in the tumor tissue.
This, in turn, should enhance the A-NK and T-LAK effectors’ activity and survival, and,
depending on the type of cytokines produced and host cells present in the tumor, should also
boost various phases of the endogenous immune response.
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3.0  CYTOKINE GENE THERAPY USING ADENOVIRALLY TRANSDUCED,
TUMOR-SEEKING A-NK CELLS2
3.1 INTRODUCTION
Although capable of eliminating circulating tumor cells from the blood-vascular system, it has
long been thought that natural killer (NK) cells play a limited role in combating established
tumors.  However, we have shown that NK cells activated ex vivo with interleukin (IL)-2 (A-NK
cells), and adoptively transferred back into tumor-bearing mice, not only localize selectively at
tumor sites 174, 205, but also mediate a significant reduction of infiltrated host lung tumors within
4-5 days 83.  Activated NK cells do not, in contrast to cytotoxic T lymphocytes (CTLs), require
recognition of specific antigen presented by MHC molecules to kill their targets, whether these
are virally infected, malignantly transformed, or otherwise aberrant cells.  In fact, the NK cell
preferentially kills cells that fail to express normal levels of MHC 2, 44.  Thus, inclusion of
activated NK cells with CTL-based immunotherapies may be crucial to avoid tumor escape via
immunoselection of tumor cells expressing low levels of, or no, MHC.
However, the in vivo survival, tumor localization, and, consequently, the anti-tumor
effect of the A-NK cells are strongly dependent on a continuous support of relatively high doses
of exogenous IL-2.  Even injections of IL-2 every 4 hours for 3 days is not sufficient to sustain
                                                 
2 Chapter 3 has been published in Human Gene Therapy. (2007.  18:701-711.)
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optimal tumor-localization 175 and anti-tumor activity of the A-NK cells.  This is probably related
to the very short half-life of IL-2 (~5 min), because impressive tumor-localization and substantial
anti-tumor activity are seen when the adoptively transferred A-NK cells are supported by
injections of the long-lived (t1/2 ~ 4 hours) polyethylene glycol-conjugated IL-2 (PEG-IL-2) 83.
However, while the use of PEG-IL-2 secures the anti-tumor function of the A-NK cells, it often
results in toxicity in the form of weight-loss and pulmonary edema/vascular leakage syndrome.
It is therefore clear that before adoptive A-NK cell therapy can be clinically applicable, it will be
necessary to circumvent the demand of A-NK cells for exogenous IL-2 in order to reduce
toxicity.
 Other cytokines, such as IL-12 and IL-18, which strongly augment NK cell proliferation
and effector functions 7, 192, 206, 207, may substitute for IL-2.  However, systemic injection of
combinations of these cytokines with IL-2 induces even more severe side effects than IL-2 alone.
For example, IL-2 in combination with IL-12 89, 208, and combinations of other cytokines, such as
IL-12 and IL-18 196, used as anti-tumor reagents, resulted in severe toxicity to the point of death
of treatment mice.  To circumvent these toxic side effects others have looked into intratumoral
injection of transduced cells, localizing the cytokine activity 128, 129.  For example, Niskioka et al.
and Satoh et al. found the delivery of IL-12 by transduced dendritic cells resulted in systemic
immunity leading to tumor regression.  For more remote tumors that cannot be injected directly,
treatments need to be tumor-specific, such as with cytokine-antibody fusions 184.  Fusion protein
technology is dependent upon appropriate antigens being well presented within the tumor for
adequate cytokine localization, which is not always the case.
Here, we set out to demonstrate that A-NK cells are capable of gene-delivery specifically
to sites of tumors and this would lead to a reduced need for exogenous IL-2 as well as greater
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anti-tumor efficacy of the A-NK cells.  We base this on our recent observation that adenovirally
transduced A-NK cells expressing green fluorescent protein (eGFP) accumulate selectively
within tumor nodules and produce eGFP at the tumor site for several days (Goding et al., 2007).
A-NK cells transduced with the gene for IL-12, a cytokine that stimulates a variety of NK cell
proliferative and cytotoxic functions, survived better in vivo, as do nontransduced coinjected A-
NK cells, in low amounts of exogenous IL-2.  Additionally, the IL-12 gene transduction of the
A-NK cells lead to a significant increase in survival of tumor-bearing mice, when compared to
mice receiving mock-transduced A-NK cells.  These data illustrate that it is possible to reduce
the tumor-infiltrating A-NK cells’ need for IL-2 support - and thereby the risk of systemic
toxicity - while maintaining anti-tumor effectiveness by transducing them with cytokine genes
such as IL-12 before the adoptive transfer.
3.2 MATERIALS AND METHODS3
3.2.1 A-NK cell preparation by negative selection
For tracking purposes, A-NK cells were generated from congenic B6.P1-Thy-1aCy
spleens as previously described 83.  Briefly, spleens were aseptically obtained, and a single cell
suspension was generated.  Red blood cells were lysed by incubating the splenocytes with red
blood cell lysing buffer (Sigma-Aldrich, St. Louis, MO) at 1ml/spleen for 2 minutes with
                                                 
3 General materials and methods pertaining to this chapter but not mentioned in this
section can be found in Chapter 2, Materials and Methods.
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swirling every 30 seconds.  Following filtration through a 70-µm filter, the remaining bulk
splenocytes were plated in culture flasks, maintained at 37
o
C and 5% CO2 in CM and 6,000
IU/ml human recombinant IL-2 (kindly provided by the Chiron Corporation, Emeryville, CA).
Following 48 hours of culture, bulk splenocytes were depleted of CD8+ and CD3+ cells, using
anti-CD8 hybridoma supernatant (Lyt2, ATCC, Manassas, VA), at 2 ml/100x106 cells, and
purified anti-CD3 Ab (clone 17A2, BD Pharmingen, Franklin Lakes, NJ), at 25 µl/100x106 cells,
respectively.  Antibody-coated cells were incubated with magnetic beads conjugated to sheep
anti-rat IgG Ab (Dynal Biotech ASA, Oslo, Norway), and A-NK cells were negatively selected
according to the manufacturer’s protocol.  Up to 72 hours after depletion, non-adherent cells
were passaged to new flasks while the adherent, purified A-NK cells were given fresh CM and
IL-2.  These plastic-adherent, A-NK cells were used on Day 5 or 6 of culture.  Routinely, these
A-NK cells were >95% Thy1.1+, >95% asGM1+, >90% NK1.1+, <2% CD8+, <3% CD3+, and
<2% CD4+.
3.2.2 Proliferation assay and cytokine production
Non-transduced A-NK cells were plated into 96-well plates at 15,000 cells/200µl/well,
following 3 washes to remove residual IL-2.  rhIL-2 (Chiron Corporation, Emeryville, CA) was
added in 10-fold dilutions and recombinant murine IL-12 (Endogen, Woburn, MA) was added at
the indicated concentrations.  After 48 hours incubation, 10µl of Cell Titer Reagent (Promega
Corporation, Madison, WI) was added to each well.  At this time a standard curve of known cell
numbers was generated and run in parallel with the treated cells.  The plates were incubated
another 3 hours at 37oC and then analyzed on a plate reader at 490nm.  For IL-12 production in
presence of titrated IL-2, 1x106 Ad-IL-12 transduced A-NK cells were cultured in 0, 6, 60, 600,
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6000 IU/ml rhIL-2 for 72 hours.  Supernatant was collected and IL-12 production was measured
using sandwich ELISAs on supernatants for murine IL-12p70 (Endogen, Woburn, MA).
3.2.3 Adoptive transfer and survival experiments
Lung tumor metastases were established by injecting B16 or MCA205 tumor cells
(3x10
5
/0.4 ml of RPMI) intravenously into C57BL/6 mice pretreated 24 hours earlier with an ip
injection of anti-asialo-GM1 antiserum (Wako PureChemicals, Wako, TX) at 25 µl in 0.5 ml
PBS to remove endogenous NK cells.  Following 24 hours of in vitro culture, Ad-IL-12, mock,
or non-transduced A-NK cells were harvested from flasks and washed.  Five million cells/ 0.4 ml
RPMI were injected iv into mice with day 3, 7 or 10 B16 lung metastases.  The transferred A-NK
cells were supported by 0.5 ml ip injections containing 60,000 IU of IL-2 in complex with
polyethylene glycol (PEG-IL-2, a kind gift from the Chiron Corporation, Emeryville, CA), at 0
and 12 hours and then either 0, 2220, 6600, or 60,000 IU (for the titration experiment) or 4,500
IU (for iv versus ip experiments) every 12 hours thereafter, up to 72 hours.  For the survival
experiments (involving B16 and MCA205 tumors) mice received only two injections of 60,000
IU Peg-IL-2 on the day of adoptive transfer.  Mice were code numbered and monitored for
survivability by two observers with no knowledge of the code.  When reaching a premorbid
condition, as defined by our IACUC, mice were euthanized and the lungs were removed, dried
and weighed (the average dry weight of the lungs from Ad-mock and Ad-IL-12 transduced A-
NK groups (Fig. 9) were 0.189g±0.01g versus 0.163g±0.03g, respectively, ensuring that the
mice, upon sacrifice, had reached the same stage of tumor development).
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3.2.4 Estimation of adoptively transferred A-NK cell infiltration of lung metastases and
tumor burden
Using the Thy1.1/1.2 congenic system the infiltration of the transferred A-NK cells was
determined as described previously83.  Briefly, one half of organ samples obtained from mice at
various time points were fresh frozen at –70
o
C.  Eight-micron thick sections of the organs were
stained with anti-Thy1.1-PE Ab (Pharmingen) at a 1:200 dilution and compared to PE-
conjugated IgG2b Ab controls.  Sections from fresh-frozen lungs with B16 tumors were stained
with a 1:1 mixture of polyclonal rabbit anti-Tyrp1209, 210 and Pmel17211, 212 antibodies (kindly
provided by Dr. Vincent Hearing, NIH, USA) and subsequently with PE-conjugated anti-rabbit
antibody (#2771, Molecular Probes Inc., Eugene, Oregon, USA) to reveal B16 tumor cells.
Fluorescent and DIC images of the tissue sections were obtained using a Nikon fluorescent
microscope and analyzed for cell numbers using MetaMorph image analysis software83.
3.3 RESULTS
3.3.1 IL-12 enhances survival of A-NK cells supported by low doses of IL-2.
A-NK cell survival depends on continuous stimulation by high doses of IL-2 both in vitro
(6,000 IU/ml) and in vivo175.  Regarding in vivo settings, it is of great interest to find ways to
maintain NK cell survival while avoiding the continuous use of systemic, toxic, high-dose IL-2
support.  Because IL-12 acts as an activating signal for NK cells192, 193, in addition to its effects
as a helper T cell type 1 (Th1) cytokine 103, 194, we tested whether A-NK cells adenovirally
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transduced to express IL-12 would require less IL-2 for their survival.  We first set out to
determine if A-NK cells transduced with an Ad-IL-12 vector, as recently described 213, could
survive in vivo without any exogenous IL-2 support.  We found that by 72 hours post injection,
none of the IL-12 gene-transduced A-NK (A-NK12) cells could be located within any of the
tissues analyzed, i.e. lung, lung tumors, liver, and spleen (data not shown).  This indicated that
IL-12 alone is not a survival factor for murine NK cells.  We then set up an in vitro assay in
which recombinant IL-12 and IL-2 were titrated to determine how much IL-2 was needed to
augment the effects of the transgenic IL-12 on NK cell survival.  As seen in Figure 10A, when
IL-2 is not provided the A-NK cells do not survive in any of the tested doses of IL-12,
confirming that this cytokine alone is not sufficient to maintain A-NK cell survival.  However,
once IL-2 is given, even at 6 IU/ml, IL-2 and IL-12 have a synergistic effect on cell survival.
The survival benefit was even more pronounced at the 600-IU/ml IL-2 level (Fig. 10A).
Increasing IL-2 to 6,000 IU/ml (the normal A-NK cell culture dose) did not enhance A-NK cell
survival above that seen with 600 IU/ml, but their survival was still greater than that of A-NK
cells cultured without IL-12 at these IL-2 levels (Fig. 10A). Thus, IL-2 is necessary as a survival
factor, but the IL-2 concentration can be greatly reduced (10-100 fold) in the presence of IL-12.
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     Figure 10.  IL-12 survival benefits on A-NK cells and IL-12 production by transduced A-NK cells depend
on IL-2.  (A) A-NK cells were plated at 1.5x104 cells per 200µl CM per well of a 96-well plate.  To the wells was
added rhIL-2 and/or rmIL-12 (ng/ml) in the concentrations indicated.  Following a 48-hour incubation, 10µl of Cell
Titer substrate was added to each well.  Plates were then read after a three-hour incubation at 490nm.  Data are
presented as number of cells/ml run in triplicate, with error bars representing SD.  (B) 5x106 A-NK cells were
transduced with Ad-IL-12 at 32 MOI in RPMI.  1x106 transduced cells were then cultured in CM in 0, 6, 60, 600, or
6,000 IU/ml IL-2.  Mock transduced cells cultured in 0 or 6,000 IU/ml IL-2 served as controls.  Supernatants were
collected after 72 hours of culture and mIL-12 was measured using ELISA, according to manufacturer’s protocol.
Values are represented as the average pg/ml IL-12p70 from two separate assays, with SD error bars.
 Having demonstrated an IL-2/-12 synergy, we next tested the ability of A-NK12 cells to
produce IL-12 when maintained at various concentrations of IL-2.  A-NK12 cells receiving no IL-
2 produced only 247 pg of IL-12 per 1x106 cells per 24 hours (Figure 10B).  However, values
reached 1,130 pg/1x106 cells/24 hours with the addition of 600 IU/ml of IL-2, but did not
increase further even after addition of 6,000 IU/ml IL-2.  These data illustrate, as could be
expected, the need for a source of IL-2 to be present for A-NK cells to express the IL-12
transgene in considerable amounts.  They also illustrate that a substantial amount of IL-12 is
produced by A-NK12 cells even when supported by low doses of IL-2.
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3.3.2 IL-12 production results in an increase in CD25 expression by transduced A-NK
cells.
IL-12 is known to induce an increase in expression of CD25 on T cells 214 and NK cells
95.  Along with the beta and gamma subunits, CD25, the alpha subunit, makes up the high
affinity complex of the IL-2 receptor.  Thus, an increase in CD25 expression induced by IL-12
could explain the reduced IL-2 dependency of the A-NK12 cells.  Indeed, 44.6% of the A-NK12
cells were positive for the expression of CD25, compared with 3.3%+ for nontransduced A-NK
(A-NKnon) cells (Figure 11).
Figure 11.  CD25 expression on A-NK cells increases following Ad-IL-12 transduction.  5x106 A-NK
cells were transduced with Ad-IL-12 at 25 MOI.  A-NK12 (filled curve) and A-NKnon (open curve) cells were stained
with anti-CD25-FITC Ab after 48 hours of culture.  Cells were analyzed by flow cytometry, collecting 5000 events
and compared with isotype control.
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3.3.3 IL-12 produced in vivo by transduced A-NK cells enhances their survival in B16
lung metastases.
Having demonstrated the capacity of A-NK12 cells to survive in vitro in low
concentrations of IL-2, we wanted to confirm this finding in vivo.  In the B16 lung tumor model,
four separate experiments demonstrated that when IL-2 was administered at low doses,
adoptively transferred A-NK12 cells survived to a much greater extent than A-NKnon/mock cells.  In
a representative experiment, in which we titrated the exogenous PEG-IL-2, a dose response was
clearly evident, with the A-NK12 cells persisting in the tumor tissue (72 hours after adoptive
transfer) in higher numbers than A-NKmock cells at all of the ranges of PEG-IL-2 below 60,000
IU tested, (Fig. 12A).
Figure 12. IL-12 expressed by transduced A-NK cells provides a survival benefit to transduced cells,
at low doses of Peg-IL-2, as well as non transduced cells when expressed locally. (A) Mice bearing day 10 B16
lung tumors received 4x106 A-NK12/mock and 5x106 A-NKnon cells iv with two injections of 60,000 IU Peg-IL-2,
followed by 4 injections at 0, 2,220, 6,600, or 60,000 IU Peg-IL-2.  (B) Mice bearing day 10 B16 lung tumors
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received either 5x106 A-NK12 and 5x106 A-NKnon iv along with 5x106 A-NKnon ip or 10x106 A-NKnon iv along with
5x106 A-NK12 ip.  At twelve-hour intervals, the mice then received two injections of Peg-IL-2 at 60,000 IU,
followed by 4 injections at 4,500 IU.  At 72 hours post adoptive transfer, mice were sacrificed and tissues harvested
(n=3). A-NK cell densities in tumors were measured as described in Materials and Methods, and represented as
number of cells (A-NK12/mock (A) and A-NKnon (B)) per square mm lung tumor tissue.  Values were found to be
statistically significant with a p value<0.05, *, and p value=0.0056, **, with error bars representing SD.
  As expected, when full dose of PEG-IL-2 was given (60,000 IU/ml every 12 hours in
the first 3 days post adoptive transfer), the exogenous A-NK cells were found in equal numbers
in lung tumors whether they were expressing IL-12 or not.  The A-NK12 cells preferentially
localized to the lung metastases rather than normal lung tissue.  This provided support that
adenoviral transduction did not diminish the transduced cells’ ability to traffic to and localize
within lung tumors.  At a PEG-IL-2 dose of 6,600 IU/12h, the A-NK12 cells were present at 75%
maximal (i.e., the value seen with 60,000 IU/12h PEG-IL-2) compared with only 15% for A-
NKmock cells (Table 1).
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Table 1.  Effect of interleukin-12 on survival of both transduced and nontransduced activated
natural killer cells in vivo.
The numbers were equally as dramatic for the lowest (2,200 IU) and no PEG-IL-2 doses
with A-NK cell densities in the tumor tissue being 4- and 8-fold better, respectively, for the A-
NK12 cells compared with A-NKmock cells (Table 1 and Figure 12A).  Thus, it appears that A-
NK12 cells are able to survive and localize to tumor tissue when supported by as little as one-
tenth the dose of exogenous IL-2 needed for A-NKmock cells (p<0.05, for all three PEG-IL-2
doses).
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3.3.4 IL-12 produced in vivo by A-NK12 cells enhances the survival of nontransduced,
coadoptively transferred A-NK cells in B16 lung metastases.
We wanted to determine whether the IL-12 produced within tumors could also maintain
the survival of nontransduced, coadministered, A-NK cells.  Using CD45 and Thy1 congeneic
systems, we could distinguish the nontransduced from the transduced effectors.  When supported
by low doses of PEG-IL-2 (2,220 IU and 6,600 IU respectively), 4.5- to 3-fold more A-NKnon
cells survived within lung tumors when coinjected with A-NK12 cells than A-NKmock cells (Table
1).  The IL-12 produced by transduced A-NK cells is, therefore, able to maintain survival of not
only the transduced cells themselves, but of neighboring A-NKnon cells as well.
3.3.5 Tumor-selective versus tumor-distant IL-12 delivery.
To evaluate the importance of the IL-12 being produced at the tumor site (as opposed to a
site distant from the tumor) on the survival of nontransduced A-NK cells in lung tumors, we
injected 5 million A-NKnon cells by the iv route plus 5 million A-NK12 cells by either the iv or ip
route.  We have previously shown that A-NK cells injected ip do not leave the ip cavity and
therefore do not localize into the lungs or lung tumors 83.  Even though ip injection of A-NK12
cells resulted in the survival of a few more A-NKnon cells (iv injected) in lung tumors compared
with the control group (which did not receive any A-NK12 cells), 8.8-fold more iv-injected A-
NKnon cells survived in lung tumors when the A-NK12 cells were injected by the iv route than by
the ip route (Fig. 12B, p value=0.0056).  Thus, in maintaining A-NK cell survival in the tumor
tissues, delivery of the IL-12 cytokine to the tumor microenvironment is superior to a tumor-
distant delivery.
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3.3.6 Intratumoral IL-12 expression by transduced A-NK cells enhances the reduction of
B16 tumor metastases.
Next, we wanted to determine how successful the local expression of IL-12 by iv injected
A-NK12 cells would be in supporting NK cell-mediated responses against established B16 lung
tumor metastases.  We began by looking at tumor tissue from mice receiving 6,600 IU/ml PEG-
IL-2 and either A-NK12 or A-NKmock cells iv.  Having IL-12 expressed within lung tumors
provided a superior benefit in regards to anti-tumor effect as well as A-NK cell survival (Fig.
13A-C).  To investigate anti-tumor responses from IL-12 produced distally rather than
intratumorally, some mice received A-NK12 cells by the ip route.  The presence of A-NK12 cells
in the ip cavity caused some reduction in tumor burden compared with control animals, but this
reduction was not significant (Fig. 13C).  By comparing the efficacy of A-NK12 cells injected iv
with that of cells injected ip, it was evident that targeting the A-NK12 cells to the lung tumors, by
iv injection, resulted in a larger tumor reduction than ip injection (p value=0.023).
3.3.7 Co-injection of nontransduced A-NK cells enhances the anti-tumor efficacy.
We next wanted to determine if the treatment efficacy of A-NK12 cells could be increased
by simultaneous administration of A-NKnon cells (that could benefit from the IL-12 produced by
A-NK12 cells in the tumor microenvironment).  This seemed to be the case since the 64% tumor
reduction seen following iv injection of A-NK12 plus A-NKnon cells was significantly greater
than the 48% reduction following iv injection of A-NK12 alone (p=0.011, Fig. 13D).  It could be
argued that the reason we did not observe a comparable tumor reduction in mice receiving A-
63
NK12 cells ip to that of mice receiving them iv, as in Fig. 13C, was due to a lack of A-NK
effector cells present to respond within the lungs.
Figure 13. Presence of IL-12 within B16 lung metastases leads to greater tumor reduction. A
representative image of a lung tumor from mice receiving A-NK12 (A) or A-NKmock (B) cells together with 6,600
IU/ml Peg-IL-2, following 2 injections of 60,000 IU Peg-IL-2 co-administered along with A-NK cells, illustrates
B16 staining (in red) contrasted with the presence of adoptively transferred A-NK cells (in green).  Images were
obtained using 20x magnification.  Bars represent 100 microns.  Note the abundant volume of A-NK cells compared
to tumors cells when IL-12 is expressed within the tumor. (C and D) Mice bearing B16 lung metastases received
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5x106 A-NKnon or A-NK12 cells (iv or ip) only (C), or in conjunction with 5x106 A-NKnon cells (iv) (D).  60,000 IU
Peg-IL-2 was administered to all mice at t=0 and 12 hours post adoptive transfer, and thereafter 4 injections of 4,500
IU Peg IL-2 were given 12 hours apart.  Data are represented as percent reduction in tumor tissue at 120 hours post
adoptive transfer compared to mice treated with IL-2 alone (n=4 (C), n=9 (D)) (*, p value=0.023, ** p value=0.011,
and ***, p value=0.0001).  Error bars represent SD.
 However, as seen in Figure 13D, mice receiving an ip injection of A-NK 12 cells plus iv
injection of A-NKnon cells (to ensure the presence of A-NK cells in the lung tumors)
demonstrated some reduction (31%) in tumor burden compared with control animals (receiving
IL-2 only), but this was significantly less than the 64% tumor reduction achieved by iv injection
of both A-NK12 plus A-NKnon cells (ensuring the presence of both A-NKnon cells and A-NK12
cells in the lung tumors) (p=0.0001).  Thus, A-NK12 cells are able to significantly boost the anti-
lung tumor activity of A-NKnon cells but only if the A-NK12 cells are also located in or near the
lung tumors.
3.3.8 Prolonged survival following treatment with IL-12 transduced A-NK cells compared
with mock transduced A-NK cells.
The results described above indicate that A-NK12 cells survive better in vivo and combat
the tumors they infiltrate better than A-NKmock cells.  To evaluate if the observed tumor
reduction was sufficient to increase survival of tumor-bearing animals, A-NK12 and A-NKmock
cells were adoptively transferred into mice with established lung tumors of B16 or MCA-205
origin.  In an early (day-3) B16 lung tumor model, a 10-day increase in survival time was found
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following iv injection of A-NK12 cells compared with A-NKmock cells or treatment with PEG-IL-
2 alone (Figure 14A, p value=0.0031).  Thus, although A-NKmock cells lose their therapeutic
efficacy when supported by only two injections of 60,000 IU of PEG-IL-2, this nontoxic regimen
of IL-2 support is sufficient to support the anti-tumor effect of A-NK12.  In fact, the therapeutic
effect of A-NK12 cells is still maintained, and significant, in mice receiving even less IL-2 (two
PEG-IL-2 injections of only 4,500 IU [Fig 14A, A-NK12 low IL-2, p value=0.0016]).
Figure 14. IL-12 prolongs the survival of mice when expressed locally by A-NK12 cells. Survivability
of mice (n=5) was monitored, as described in Materials and Methods, after the mice received 5x106 A-NKnon, A-
NKmock or A-NK12 cells.  The survivability of mice bearing day 3 B16 (A), day 7 B16 (B), or day 7 MCA205 (C)
lung metastases was plotted using the Kaplan-Meier method for the number of days post tumor induction.  Statistical
significance was calculated, using log-rank test, for mice receiving A-NK12 compared to A-NKmock cells, with p
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values=0.0031 (A), 0.0019 (B), and 0.0158 (C).  Δ = A-NKmock low IL-2: A-NKmock plus 2 injections of 4,500 IU
(low) Peg-IL-2; ▲=A-NKmock: A-NKmock plus 2 injections of 60,000 IU (high) Peg-IL-2; =IL-2 only: 2 injections
of high Peg-IL-2 only; =A-NK12 low IL-2: A-NK12 plus low Peg-IL-2; =A-NK12: A-NK12 plus high Peg-IL-2;
=tumor only: tumor cells only; =A-NKnon: A-NKnon plus high Peg-IL-2.  Some data from panel (A) have
previously appeared as a separate figure in a Cancer Gene Therapy article (Goding et al., 2007).
To determine the efficacy of A-NK12 cells in a more aggressive advanced tumor setting,
mice bearing 7-day-old B16 lung tumor metastases were treated with A-NK12 cells.  These mice
survived a median 26 days compared with 20 days for mice receiving A-NKmock cells (Figure
14B, p value=0.0019).  Treatment with A-NK12 cells as compared with A-NKnon cells also
prolonged the survival of mice bearing day-7 MCA-205 lung tumors, by 7.5 days (Figure 14C, p
value=0.0158).  This clearly illustrates the enhanced anti-tumor efficacy of A-NK12 cells
compared with A-NKnon/mock cells and demonstrates the advantage of using adenovirally
transduced A-NK cells to deliver and express cytokines specifically within lung tumors.
3.4 DISCUSSION
We suggest that adoptive transfer of A-NK cells, adenovirally transduced with cytokine genes,
can be used to ensure the presence of cytokines in the tumor tissue.  Our data show ex vivo-
transduced A-NK cells are clearly capable of expressing a transgene in the tumor
microenvironment following adoptive transfer.  Depending on which cytokine gene the A-NK
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cells express, this strategy may help support the adoptively transferred NK cells themselves,
endogenous NK cells or cells involved in adaptive immunity, such as dendritic cells and T cells.
We found that IL-12 gene transduction of A-NK cells significantly reduced their demand for
exogenous IL-2 as a survival factor both in vitro and in vivo, reducing concerns of IL-2-related
toxicity.  In addition, greater survival of nearby, nontransduced, A-NK cells was observed in
vivo.  Most importantly, at low doses of exogenous IL-2 support, selective IL-12 gene therapy to
lung tumors using IL-12 gene-transduced A-NK cells resulted in significantly greater anti-tumor
responses, as compared with nontransduced A-NK cells.
IL-2 is involved in a number of ways in generating and perpetuating anti-tumor
responses.  NK and T cells require it for activation, proliferation, and survival 61.  IL-2 is a key
component in triggering other anti-tumor cytokines cascades, such as interferon (IFN)-γ 215 and
tumor necrosis factor (TNF)-α 216.  We have also found that IL-2 is needed to ensure trafficking
to and localization within established tumors by adoptively transferred A-NK cells 175.  The
amount of IL-2 that can be given to support the A-NK cells, however, is greatly limited by the
adverse effects IL-2 has when applied at high doses over an extended period 88, 217.  To solve this
problem, we investigated whether provision of the A-NK cells, via adenoviral gene transduction,
to produce IL-12 would enable them to survive and function in vivo without the support by high
and toxic doses of IL-2.
When recombinant murine IL-12 was added to A-NK cell cultures, we found, as
expected, enhanced A-NK cell proliferation at all IL-2 levels tested.  However, the A-NK cells
died rapidly if IL-2 was absent, indicating that although IL-12 works synergistically with IL-2 in
terms of survival and proliferation, IL-12 alone is not a survival factor for the A-NK cells.
Accordingly, A-NK12 cells also survived much better in vitro at low levels of IL-2 compared
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with A-NKmock cells, but when no exogenous IL-2 was given most of the A-NK12 cells died
within 24 hours.  It was not surprising, therefore, that the ability of the transduced A-NK cells to
produce IL-12 depended on the presence of IL-2.  However, maximal IL-12-production (>1.1
ng/24 hours/1x10
6
 cells) was achieved at low IL-2 levels (600 IU/ml IL-2).  It is very likely that
this increased sensitivity to IL-2 induced by the IL-12 gene transduction is caused by the IL-12-
driven upregulation of CD25.
Adoptive transfer experiments revealed that IL-12 gene transduction of the A-NK cells
prior to injection enhanced their survival in vivo as well.  When supported by high (120,000
IU/day) doses of IL-2, the densities of A-NKmock and A-NK12 cells in lung tumors were the same.
However, lowering the IL-2 support by 10-fold resulted in an almost complete loss of the A-
NKmock cells, whereas A-NK12 cells were found at 75% of maximal density in the lung tumors.
Furthermore, A-NKnon cells survived significantly better in lung tumors when coinjected with A-
NK12 cells than with A-NKmock cells, due to the benefit of IL-12 produced by A-NK12 cells at the
tumor site.
The enhanced survival of the A-NK12 cells compared with A-NKmock/non cells translated
into a therapeutic benefit, in that a significantly greater reduction in growth of infiltrated tumors
was seen following treatment with A-NK12 cells versus A-NKmock/non cells.  Furthermore, the
therapeutic effect of the combined treatment with A-NK12 and A-NKnon cells was superior to
either treatment alone, indicating that not only survival, but also the anti-tumor effector
mechanisms of A-NKnon cells is enhanced by IL-12 (or IL-12-induced IFNγ) produced by nearby
A-NK12 cells.
To evaluate whether the observed effect on A-NK cells survival and anti-tumor potential
was dependent on the presence of IL-12 produced locally, i.e., in the tumor microenvironment,
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or at a site distal from the lung tumors, A-NK12 cells were, in some experiments, injected by the
ip route.  Even though ip injected A-NK cells do not leave the ip cavity and therefore do not
home to tumor sites in the lungs 83, the IL-12 (and/or IFNγ) produced by these cells could reach
systemic level high enough to stimulate intratumoral A-NK cells.  Whereas IL-12 was
undetectable in serum from any of the treated animals, IFNγ levels were increased in all animals
receiving A-NK12 cells, compared with mice receiving IL-2 only, despite the route of their
administration.  IFNγ was measured in the range of 1000-1500 pg/ml in the serum of mice
receiving A-NK12 cells whereas approximately 250 pg/ml was demonstrated in serum of mice
receiving IL-2 only treatment.  This provides evidence that, despite direct proof for IL-12
production by A-NK12 cells in vivo, unlike with the production of GFP within tumors previously,
IL-12 is being produced by the A-NK12 cells in the tumors.  Although iv injected A-NKnon cells
survived slightly better and displayed slightly enhanced anti-tumor activity when coadministered
with A-NK12 cells ip compared with animals not receiving A-NK12 cells, both parameters were
significantly better in animals receiving the A-NK12 or A-NK12 plus A-NKnon cells iv, illustrating
even further the effects of IL-12 production in A-NK12 recipient mice.  Thus, tumor-localization
of A-NK12 cells seems to be a prerequisite for achieving the full IL-12 effects generated by these
cells.
We have recently demonstrated that the morphology (“loose” versus “compact”) of
experimental mouse lung tumors predicts their permissiveness to A-NK and T cell infiltration 218.
In the experiments described above, measurements of A-NK cell tumor homing and anti-tumor
effect were performed on lung tumors of the infiltration-permissive, “loose” phenotype, usually
comprising 65-75% of all B16 lung metastases.  However, despite the fact that most metastases
of the infiltration-resistant, “compact” phenotype became only poorly infiltrated by the injected
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A-NK cells, the overall efficacy of the A-NK12 cell therapy was highly significant in both day-3
and -7 tumor models as judged by survival time of treated animals (resulting in 10- and 7-day
increases, respectively).  Although such prolongation in survival, especially in the aggressive
B16 model, is impressive given the fact that only one treatment with about five million effector
cells was given, it is clear that the anti-tumor effect is only transient and that the remnants of the
tumors attacked by the A-NK cells continues to grow exponentially.  Apparently, no efficient
adaptive immune responses against the B16 or MCA-205 tumors were induced, despite the
massive destruction of tumor tissue by the A-NK cells and the intratumoral presence of the Th1
cytokines, IL-12 and IFNγ.  Experiments are in progress to elucidate whether any adaptive
responses are generated at all after A-NK12 treatment or whether the low MHC-I expression,
especially by the B16 tumors, allows the evasion from MHC-restricted CTLs.  If no signs of
adaptive immunity are detected, it is possible that such immunity can be induced by
cotransducing the A-NK12 cells with genes encoding for additional immunostimulatory factors
such as granulocyte-macrophage colony-stimulating factor (GM-CSF), CD40, and so on.
In conclusion, we have demonstrated that A-NK cells can be effectively used for cytokine
gene therapy, due to their ease of transduction with adenoviral vectors expressing transgenes
encoding immunostimulatory cytokines such as IL-12.  The success of this novel mode of gene
therapy is evident in greater survival of both A-NK12 and bystander A-NKnon cells, allowing for
efficient A-NK cell-based cancer treatment that is not dependent on continuous support by high
and toxic doses of exogenous IL-2.  Although the A-NK12 treatment leads to significant tumor
reduction and survival prolongation, it does not result in long-lasting inhibition of tumor growth.
Nevertheless, these experiments demonstrate the potential of employing cytokine gene-
transduced A-NK cells in cancer immunotherapy and we predict that, because A-NK cells can be
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transduced to express several genes simultaneously 213, we will eventually be able to manipulate
the intratumoral cytokine milieu such that long-lasting adaptive anti-tumor responses can be
generated and maintained without systemic injection of cytokines and therefore without the
induction of limiting side effects and toxicity.
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4.0  ENHANCING A-NK12 EFFICACY WITH TNFα
4.1 INTRODUCTION
Treatment with IL-12 gene-transduced A-NK cells has been effective in promoting significant
benefits with respect to increased animal survival and decreased cytokine toxicity, but the mice
eventually succumbed to the tumor burden.  Since the A-NK cells are relatively short-lived cells,
it is very likely that as A-NK cell numbers diminish in tumors, the overall anti-tumor response
was subsequently diminished.  Regardless of the tumor-destruction mediated by the treatment
and the presence of pro-inflammatory cytokines IL-2, IL-12, and IFNγ, the survival benefit was
limited to 6-10 days and therefore did not indicate that cellular adaptive anti-tumor immune
response were being induced.  To compensate for A-NK-IL-12’s lack of long-term host anti-
tumor induction, we decided to investigate the addition of another immune-promoting cytokine,
TNFα, to the IL-12 transduction.  This seems to be an appropriate choice in that TNFα functions
to increase the permeability of vasculature to allow immune cells and humoral immune factors to
enter an inflamed tissue.  Thus, TNFα  could enhance the movement of cells, including
endogenous and transferred NK cells into the tumor48, 219.  TNFα may stimulate and mature
intratumoral DCs220, and this, along with the presence of antigens released from tumor cells
killed by the A-NK12 cells and the presence of the proinflammatory cytokines IL-12 and IFNγ
within tumors, may then lead to the induction of a Th1-polarized anti-tumor immune response.
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TNFα could also benefit the A-NK12 cells themselves in that TNFα has been shown to increase
the proliferation of NK cells221. Finally, when combined with IL-2, TNFα may increase
lymphokine activated killer activity222.  Thus, an increased efficacy of the A-NK cell treatment
and possibly induction of adaptive anti-tumor responses could be expected when TNFα gene-
transduction is added to A-NK12 cell treatment.
We show here that in spite of considerable production of TNFα and an inhibitory effect
of A-NK12/TNFα cell supernatants on B16 growth in vitro, as well as a remarkable persistence in
vivo of A-NK cells transduced with both IL-12 and TNF, co-transducing A-NK12 cells with
TNFα did not result in a robust and significant survival benefit compared to IL-12 transduction
alone.
4.2 MATERIALS AND METHODS4
4.2.1 Animals and viral vectors
C57BL/6, B6.PL-Thy1a/CyJ, and NOD.CB17-Prkdc/J mice were purchased from Jackson
laboratories (Bar Harbor, ME).  The animals were housed in a specific pathogen free facility and
the University’s IACUC authorized their use.  The recombinant murine TNFα adenoviral vector
used in the proceeding studies were E1/E3 deleted replication-defective type 5 adenoviruses
18
(obtained from the Preclinical Vector Core Facility, University of Pittsburgh).
                                                 
4 General materials and methods pertaining to this chapter but not mentioned in this
section can be found in Chapter 2 or 3, Materials and Methods.
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4.2.2 TNFα production and B16 growth inhibition
A-NK cells were transduced with Ad-mTNFα at 5, 25 or 50 MOI, Ad-IL-12 at 20 MOI
or together at 5 MOI TNFα/20 MOI IL-12 (for cytokine analysis) or 25 MOI TNFα/20 MOI IL-
12 (for B16 growth inhibition).  A-NK cells transduced with 50 MOI Ad-TNFα were cultured
over the course of 96 hours.  Supernatant was collected every 24 hours.  For A-NK cells
transduced with TNFα and IL-12, supernatants were obtained 72 hours after initial viral
incubation.  Supernatants were then tested for TNFα production using multi-cytokine Luminex
assay (Luminex core facility, University of Pittsburgh) or added to B16 cell cultures diluted in
complete media. After a 48-hour incubation, 10µl of Cell Titer Reagent (Promega Corporation,
Madison, WI) was added to each well.  The plates were incubated another 3 hours at 37oC and
then analyzed on a plate reader at 490nm.
4.2.3 Adoptive transfer and survival experiments
Lung tumor metastases were established by injecting B16 tumor cells (3x10
5
/0.4 ml of
RPMI) intravenously into NOD.CB17-Prkdc/J and/or C57BL/6 mice pretreated 24 hours earlier
with an ip injection of anti-asialo-GM1 antiserum (Wako PureChemicals, Wako, TX) at 20 µl in
0.5 ml PBS to remove endogenous NK cells.  Following 24 hours of in vitro culture, Ad-IL-12,
Ad-TNFα, Ad-TNFα/IL-12, or mock-transduced A-NK cells were harvested from flasks and
washed 3 times.  Five million cells/ 0.4 ml RPMI were injected iv into mice with day-7 B16 lung
metastases.  The transferred A-NK cells were supported with 0.5 ml ip injections containing
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60,000 IU of IL-2 in complex with polyethylene glycol (PEG-IL-2, a kind gift from the Chiron
Corporation, Emeryville, CA), at 0 and 12 hours.
4.3 RESULTS
4.3.1 A-NK12 cell therapy is not dependent on endogenous T, B or NK cells.
Before evaluating the ability of TNFα to further improve the A-NK12 cell-based therapy,
we wanted to determine if the survival increases we have seen previously with A-NK12 cell
therapy were due primarily to the A-NK cells only or if the host has contributed to the anti-tumor
therapy via T, B or NK cells.  We therefore conducted an experiment involving a comparison of
A-NK12 cells transferred into wild-type (WT) mice versus NOD-SCID mice.  NOD-SCID mice
are deficient for T and B cells and NK cell activity.  Before assessing the survival of these two
types of mice following A-NK12 therapy, we needed to ensure that A-NK12 cells are not impeded
in any way in trafficking to lung tumors in the NOD-SCID mice, as this could skew results.  As
expected, A-NK12 cells were found in tumors at the same level in both WT and NOD-SCID mice
(data not shown).  As seen in Figure 15, WT animals receiving A-NK12 survived 8 days longer
than WT animals receiving A-NKmock cells (p value=0.0012).  Interestingly, NOD-SCID mice
survived an equal amount of time following A-NK12 treatment (Figure 15), illustrating a lack of
involvement of host anti-tumor activity mediated by T, B, and NK cell.
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Figure 15.  C57BL/6 mice and NOD-SCID mice bearing B16 lung tumors survive significantly longer
following A-NK12 cell therapy than A-NKmock therapy.  5 x 10
6
 mIL-12 or mock transduced A-NK cells were
injected i.v. into 7-day B16 tumor-bearing WT and NOD-SCID mice, and supported with 2 injections of 60,000
IU/ml PEG IL-2.  Survival of mice was determined in a blinded fashion as described in Material and Methods and
plotted using the Kaplan-Meier method.  Log-rank test demonstrated a significant difference in survival time
between mice receiving mock transduced A-NK cells and mIL-12 transduced A-NK cells (p value<0.005, n=5,
except for IL-12 in C57 mice where n=4).
4.3.2 TNFα-transduced A-NK cells can produce TNFα and the production is increased
following IL-12 co-transduction.
Although IL-12 has been successful in enhancing A-NK cell therapy without generating
toxicity, this does not seem to be sufficient to boost long-term adaptive host immunity, according
to the survival readout.  An early initiator of inflammation, TNFα, activates DCs and promotes
mock/12 in C57 vs NOD-SCID
0 5 10 15 20 25 30
0
10
20
30
40
50
60
70
80
90
100
110
mock in C57
IL-12 in C57
mock in NOD-SCID
IL-12 in NOD-SCID
Days post tumor induction
77
CTL generation223, 224. In addition to its other beneficial effects listed above, TNFα is therefore
an attractive choice to add to the A-NK-12 therapy to further promote adaptive immune
responses.  We began by demonstrating the ability of A-NK cells to produce TNFα following
adenoviral transduction.  Figure 16A demonstrates that TNFα can be detected in supernatant in
the range of ng/ml from A-NK cells transduced at 50 MOI with Ad-TNFα.  Production peaks
around 72 hours post transduction at 1750 pg/ml and can be measured out to at least 96 hours.
Furthermore, Figure 16B shows a 25-fold increase in TNFα production with 5 MOI virus
compared with no virus.  When the A-NK cells were cotransduced with IL-12, the level of TNFα
increased 2-fold from that seen with TNFα  transduction alone (Fig. 16B, 109pg/ml vs.
216pm/ml for TNFα and TNFα/IL-12, respectively).
Figure 16. TNFα is produced by transduced A-NK cells.  (A) 5x105 A-NK cells were transduced with
Ad-TNFα at 50MOI or (B) 5x105 A-NK cells were transduced with Ad-TNFα or Ad-TNFα/IL-12 at 5 and 5/20
MOI, respectively, in RPMI.  Transduced cells were then cultured in CM with 6,000 IU/ml IL-2.  Non-transduced
cells served as control.  Supernatants were collected at the times indicated (A) or after 72 hours of culture (B) and
TNFα was measured in a luminex assay.
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4.3.3 Anti-B16 activity of supernatants from A-NK12/TNFα cells.
We wanted to determine the combined effect of TNFα and IL-12 in tumor cell killing
mediated by supernatants from transduced A-NK cells.  When supernatants from TNFα gene-
transduced A-NK cells were added to B16 cell cultures, fewer B16 cells survived compared with
no virus and mock virus controls (Fig. 17).  There was a slight decrease in the number of B16
cells seen with TNFα over IL-12 alone but this was only obvious at the 1:2 dilution.  The effect
on B16 cell growth was more pronounced when TNFα and IL-12 are combined, as seen at the
1:8 dilution of supernatant (Fig. 17, p value<0.001).  These data illustrate that supernatants from
A-NK cells transduced with TNFα, in addition to IL-12, inhibit the growth of B16 cells.  We
also investigated the ability of A-NK cells transduced with TNFα and IL-12 to directly kill B16
cells in a 4-hour chromium release assay.  Unlike with B16 growth inhibition, A-NK cytotoxicity
was not significantly enhanced by co-transducing A-NK12 cells with TNFα.
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Figure 17.  TNFα adds to the IL-12 induced growth inhibition of B16 cells in vitro.  15x103 B16 cells
were set up in 96-well culture plates for 24 hours.  Supernatants from cultures of A-NK cells transduced with IL-12,
TNFα, or IL-12 and TNFα, at the MOI indicated, were added at varying dilutions to the B16 cell cultures.  B16 cells
were then cultured for another 48 hours.  Cell titer assay substrate was added to the wells and following a 3-hour
incubation period the plates were read on a plate reader at 490nm.  Values are given in average o.d. value from wells
run in triplicate.
4.3.4 Transduction with TNFα and IL-12 enhances in vivo survival of adoptively
transferred A-NK cells.
Having demonstrated that TNFα can be over-expressed by transduced A-NK cells,
enhanced with IL-12 co-transduction, and an improved B16 cell growth inhibition by A-
NK12/TNFα cell-secreted factors, we set out to determine if this could translate into improved anti-
tumor responses in an in vivo setting.  We decided to investigate the early effects of TNFα in
terms of the dynamics of the lung and tumor microenvironment infiltrate.  We began by looking
at the survival of adoptively transferred A-NK cells in B16 lung tumor-bearing animals.  Mice
were given 5 million A-NK12, A-NKTNFα, or A-NK12/TNFα cells iv and two ip injections of PEG-
IL-2 (60,000 IU/ml), one given at the time of the injection of A-NK cells, the next given 12
hours later.  At 96 hours after adoptive transfer we found, as expected based on previous
experiments, relatively few A-NK cells in the lung tumors when transduced with IL-12 or mock
virus (approximately 53.4 A-NK12 cells/mm2 tumor tissue in the lungs, and only 10.1 A-NKmock
cells/mm2 (Fig. 18A and B)).  This low A-NK cell density at a late time point is not surprising
considering the fact that IL-12 on its own is not a survival factor for A-NK cells and that
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exogenous IL-2 support of the NK cells was administered only the first day (120,000 IU PEG-
IL-2 given within 12 hours of the A-NK cell injection).  We
Figure 18. Presence of TNFα within B16 lung metastases leads to greater presence of A-NK cells. (A)
Mice bearing day-7 B16 lung metastases received 5x106 A-NKmock, A-NK12, A-NKTNFα, or A-NK12/TNFα cells iv.
60,000 IU PEG-IL-2 was administered ip to all mice at t=0 and 12 hours post adoptive transfer.  Data are
represented as average number of A-NK cells per square mm tumor tissue at 96 hours post adoptive transfer
compared (n=5) (*, p value=0.0021).  Error bars represent SD.  (B-D)  Representative images of a lung tumors from
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mice receiving A-NK12 (B), A-NKTNFα (C), or A-NK12/TNFα illustrating the presence of adoptively transferred A-NK
cells (in red).  The B16 tumor areas have been outlined in yellow for identification purposes.  Images were obtained
using 10x magnification.  Note the high density of A-NK cells when IL-12 and TNFα are expressed within the
tumor compared with IL-12 alone (B and D).
were, however, surprised to find an abundance of A-NK cells persisting in lung tumors, when
they had been transduced with TNFα.  There was a 2.4-fold increase in the number of cells if
they expressed TNFα as opposed to IL-12 (Fig. 18A and C), although not statistically
significant.  However, when the A-NK cells were cotransduced with IL-12 and TNFα, the cell
numbers reached levels of 528/mm2 tumor tissue (Fig. 18A and D, p value=0.0021), i.e. a 9.9-
fold increase compared to A-NK12 cells.  We also tested for differences in the presence of
endogenous cells, such as CD4+ and CD11c+ cells, but each treatment resulted in relatively
equal numbers.
4.3.5 TNFα, when combined with IL-12, does not result in significant survival of tumor-
bearing mice.
We next wanted to know if the TNFα/IL-12 induced increases in the amount of A-NK
cells present within lung tumors, along with the production of TNFα, IL-12 and possible down-
stream (TNFα)-induced pro-inflammatory cytokines and chemokines, could translate into a
significant enhancement of survivability in tumor-bearing mice.  A-NK12/TNFα cells were injected
into B16 tumor-bearing animals.  In a 7-day B16 model, A-NK12/TNFα cell treated mice survived
8 days longer than A-NKmock cell treated mice (Fig. 19, p value=0.012).
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Figure 19.  Co-transducing A-NK12 cells with TNFα provides an increase in survival, albeit non-
significant, in mice bearing B16 lung tumors.  B16 tumor-bearing mice received 5x106 A-NK12 cells.
Survivability was monitored, as described in Materials and Methods, and plotted using the Kaplan-Meier method for
the number of days post tumor induction.  Statistical significance was calculated, using log-rank test, for mice
receiving A-NK12 compared with A-NK12/TNFα cells in the B16 background, p value=0.063 (n=5 for all groups except
A-NK12 and A-NK12/TNFα where it was n=3).
Compared with A-NK12 cell treated mice, however, there was only a 4-day difference in survival
(p value=0.063).  This indicates a lack of improved therapy of A-NK12/TNFα treatment, over A-
NK12 treatment alone, contrary to the significant A-NK cell survival benefit by combining TNFα
and IL-12, as described above.
Considering that induction of adaptive immunity could take place without being “visible”
by survival as endpoint, we investigated if the initiation of T cell responses was in fact being
induced by A-NK12/TNFα treatment.  For these studies, we used the OT-I/MO5 model.  MO5/OT-I
offers the B16 tumor cell line that stably expresses ovalbumin and the ovalbumin transgenic,
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MHC-I restricted (OT-I) CD8+ T cell, which recognizes the OVA-derived peptide, SIINFEKL.
However, two out of three attempts incorporating this model with A-NK12 or A-NK12/TNFα cell
therapy resulted in no signs of OT-I cell proliferation in draining lymph nodes.  From these
results, TNFα, in the capacity it has been employed, was not able to significantly enhance the
therapeutic efficacy of A-NK12 cells, neither in terms of improved survival of the treated animals,
nor at the level of T cell activation.
4.4 DISCUSSION
Here we have shown that A-NK cells can be transduced with multiple genes, in this case IL-12
and TNFα.  The expression of these genes resulted in a high production of both cytokines and
greater TNFα with TNFα/IL-12 co-transduction than if the cells were transduced with the TNFα
gene alone.  It was hypothesized that transduction with this additional cytokine gene would
improve the efficacy of the A-NK cell treatment and possibly promote adaptive immunity unlike
the apparent inability of IL-12 alone to accomplish this.  We found, however, that the co-
transduction of A-NK cells with IL-12 and TNFα did not promote T cell activation and gave
only a modest, non-significant 4-day increase in survival.
At the 96-hour time-point, when one day of PEG-IL-2 support has been insufficient in
maintaining A-NK cell survival, even with IL-12 gene transduction, the presence of a high
number of A-NK12/TNFα cells in lung metastases was a remarkable finding.  This increased A-NK
cell survival trend was also observed with the transduction of the A-NK cells with TNFα alone,
although not significantly greater compared to IL-12 alone.  When we further investigated how
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this increased presence of cells would translate in survivability, we found a 4-day increase in
overall survival when mice received A-NK12/TNFα cells compared to A-NK12 cells, but these data
turned out to be non-significant.  Of course, with a larger number of mice per group, the mouse
survival difference could turn out to be significant.  We believe that two conclusions can be
drawn from these results.  First, the addition of TNFα gene transduction does not improve the A-
NK cell treatment to the extent that can be measured with survivability readouts.  Second, the
number of A-NK cells present within the lung tumors does not correlate strictly with the
therapeutic outcome, i.e. the survival of recipients.  The abundance of A-NK cells when co-
transduced with IL-12 and TNFα would suggest a greater effector population with the capacity
to kill tumor targets.  Having 9.9-fold more A-NK cells present in the lungs with IL-12/TNFα
gene transduction compared to IL-12 alone, we imagined, therefore, a more prolonged survival
than the short, 4-day increase we observed.  It was a little surprising that while supernatants from
IL-12/TNFα transduced A-NK cells were able to reduce the growth of B16, the cytotoxicity of
the A-NK cells, as measured in a 51-Cr release assay, was not improved by the TNFα co-
transduction.  This result may not be so surprising, however, since the 51-Cr release assay was
only run for 4 hours, and this may not have been sufficient TNFα  expressed to mediate a
substantial difference in tumor cell killing compared to A-NK12 cells.  The growth inhibition
study involved supernatant containing TNFα accumulated over a 24-hour period.
It could be that TNFα maintains the presence of the A-NK cells in lung tumors without
significantly enhancing their direct anti-tumor functions.  The increased persistence of A-
NK12/TNFα cells beyond that seen with IL-12 transduction alone is somewhat puzzling in light of
the established apoptotic role of TNFα, including NK cell apoptosis225.  TNFα may stimulate the
production of PGE2 by the immune system, which can then lead to the suppression of LAK cell
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activity, in mice226 and humans227.  These and other negative effects of TNFα, most prominently
its major role in inducing toxicity as seen during sepsis, should be considered for the
effectiveness of TNFα.  Although the mechanisms involved in the double transduced A-NK cells
persisting to such a high degree without mediating greater therapy have not been elucidated, in
any case this phenomenon provides a great deal of promise for future use of transduced A-NK
cells.
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5.0  IMPORTANCE OF IFNγ FOR THE ANTI-TUMOR EFFECT OF A-NK12
TREATMENT
5.1 INTRODUCTION
The fact that mice eventually succumb to tumor burden after A-NK12 cell treatment, as
disparaging as this may be, does not mean that the host does not or cannot contribute to the anti-
tumor effect, in a non-T, B, or NK cell manner.  While A-NK12 cells do not lead to induction of
long-term adaptive immunity they do provide greater survival of mice either via their cytolytic
function or by releasing and inducing the release of various cytokines, or both.  For example,
IFNγ is produced in high amounts by A-NK12 cells and we believe its production is also induced
in the host by the IL-12 from A-NK12 cells.  IFNγ has been extensively shown to be a key
component of NK cell functions.  Apart from granule exocytosis of perforin and granzymes, NK
cells kill target cells through the indirect action of IFNγ12.  If adaptive immune reactivity had
been induced, the IFNγ could also help the CTLs via MHC upregulation which would improve
CTL recognition of the tumor cells49.  Also IFNγ is known to act as a strong inducer of
macrophage activity228.  Based on our finding that the A-NK12 cell therapy is fully effective in
NOD-SCID mice (Chapter 4), we believe that host-mediated anti-tumor effects, if important at
all, could be mediated via IL-12 and/or IFNγ activated macrophages rather than T, B, or NK
cells.
87
Using IFNγ KO mice, we determined the importance of IFNγ for the anti-tumor activity
of the A-NK12 cell treatment and identified which source, the A-NK cells and/or the host, is
important in supplying the IFNγ by comparing the survival of IFNγ KO and WT mice receiving
A-NK12 cells derived from IFNγ KO and WT mice.
5.2 MATERIALS AND METHODS5
5.2.1 Animals
C57BL/6 and B6.129S7-Ifng/J mice were purchased from Jackson laboratories (Bar
Harbor, ME).  The animals were housed in a specific pathogen free facility and the University’s
IACUC authorized their use.
                                                 
5 General materials and methods pertaining to this chapter but not mentioned in this
section can be found in Chapter 2 or 3, Materials and Methods.
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5.3 RESULTS
5.3.1 A-NK12 cells generated from IFNγ KO mice produce high amounts of IL-12 and
home to established B16 lung tumors.
With the goal of determining the impact of IFNγ in A-NK12 cell therapy, we needed to
determine first if A-NK cells derived from IFNγ KO mice would be capable of functioning like
A-NK cells derived from WT mice, i.e. could they be transduced to express IL-12 and still traffic
to tumors if they are missing the ability to produce IFNγ.  We found that A-NK cells can be
successfully generated from IFNγ KO mice and possess a similar phenotype as WT A-NK cells.
Following Ad-IL-12 transduction, a high level of IL-12 was produced by IFNγ KO A-NK cells,
roughly 2100 pg, comparable to that seen with A-NK12 cells derived from normal mice (Figure
20).
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Figure 20. IL-12 production is comparable in transduced A-NK cells from C57BL/6 and IFNγ KO
mice.  A-NK cells generated from WT and IFNγ KO donor mice were transduced at 20 MOI of Ad-IL-12.  3x106
transduced cells were cultured for 72 hours after the cells were washed 3x in an excess volume of RPMI.
Supernatants were then collected and tested for IL-12 production with a Luminex assay.  Values are calculated for
1x106 cells per 24 hours.   
 We also confirmed that IFN γ KO A-NK 12 cells, as expected, do not produce IFN γ, unlike WT
A-NK12 cells (data not shown), which produce approximately 25ng/million cells/24 hours.
Finally, we measured a similar level of infiltration by IFNγ KO A-NK12 cells, compared to WT
A-NK12 cells, into B16 lung tumor metastases, 48 hours after adoptive transfer (Figure 21).
Figure 21.   A-NK12 cells from C57BL/6 and IFNγ KO mice traffic to and localize within lung
metastases.  3.5x106 A-NK12 cells were intravenously injected into WT recipient mice and supported with 2 ip
injections of PEG-IL-2 at 0 and 12 hours after adoptive transfer.  48 hours after cell injection mice were euthanized,
lungs removed, and cells enumerated as previously described.   
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5.3.2 IFNγ supplied by the host is a critical factor for the anti-tumor effect of A-NK12
treatment.
We wanted to determine if the high presence of IFNγ we have observed in the serum of
A-NK12 cell treated mice (generated by the A-NK12 cells, the host, or both) is important for anti-
tumor survival benefits and from which source, i.e. A-NK cell-derived or host-derived.  We
conducted two separate experiments in which 4.5x106 A-NK12 cells, generated from wild-type
C57BL/6 and IFNγ KO mice, were adoptively transferred into wild-type mice or IFNγ KO mice.
These mice received 120,000 IU PEG-IL-2 (60,000 IU at time of transfer and again 12 hours
later) and were monitored for survival.  As we have seen on a consistent basis, there was a
significant 6-day increase in the survival of WT mice receiving normal A-NK12 cells compared
to normal A-NKmock cells (Figure 22, p value=0.0031).
Figure 22. IFNγ produced by the host has a greater impact on the survival of tumor-bearing mice
than IFNγ produced by the IL-12 transduced A-NK cells.  4.5x106 WT A-NKmock or WT or IFNγ KO A-NK12
cells were injected into WT or IFNγ KO recipient mice bearing day-7 B16 lung tumors, as indicated in the legend.
Day-7 B16: WT vs. IFNg  KO
0 10 20 30 40
0
10
20
30
40
50
60
70
80
90
100
110
WT mock in WT
WT 12 in WT
WT 12 in KO
KO 12 in WT
KO 12 in KO
KO control
Days post tumor inoculation
91
Survivability was monitored, as described in Materials and Methods, and plotted using the Kaplan-Meier method for
the number of days post tumor induction.  Statistical significance was calculated, using log-rank test (n=5 for all
groups except WT A-NK12 into KO mice, where it was n=4).  These results represent 1 of 2 identical experiments
that produced similar results without significantly different survivals in the same groups of the two experiments.
Median survivals in days for experiment 1 (presented above)/ experiment 2 are 21-21 for WT mock in WT, 27-29
for WT 12 in WT, 17-17 for WT 12 in KO, 27-29 for KO 12 in WT, and 10-10 for KO 12 in KO.  Median survival
of IFNγ KO control mice was 16 days and only included in experiment 1.
In both experiments, there was no difference in survival of WT tumor-bearing mice when A-
NK12 cells were generated from WT or IFNγ KO mice, illustrating a minimal requirement for A-
NK cell-derived IFNγ production.  However, when WT A-NK12 cells were administered to IFNγ
KO tumor-bearing recipients, the mice survived a median 17 days, a 10-day decrease from WT
A-NK12 in WT mice (p value=0.0029), and, more surprisingly, a 4-day decrease from mock
control mice (p value=0.0029).  These data represent a clear role for IFNγ produced by the host.
We included in one experiment a group of IFNγ KO mice to serve as a control for B16 tumor
development in these mice.  The difference in survival between these mice and IFNγ KO mice
receiving WT A-NK12 cell treatment was only a day.  Their survival seems to point to a faster
growth rate of B16 tumors in IFNγ KO mice, as we have seen a 4-day increase in survival of B16
lung tumor-bearing WT mice that had received A-NKmock cells.  In previous experiments, mice
receiving these cells do not survive significantly longer than WT mice not receiving treatment.
Finally, in the situation where no IFNγ could be made, namely A-NK12 cells from IFNγ KO mice
injected into IFNγ KO recipients, all mice surprisingly died within 3 days of the adoptive
transfer.  Upon further investigation, it was apparent that mice died due to what appeared to be
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cytokine-induced toxicity (including vascular leakage) rather than advanced growth of tumor
(i.e. both the tumor burden of the lungs and extrapulmonary sites at this time point were low or
undetectable macroscopically).  Interestingly, in both experiments one IFNγ KO mouse receiving
WT A-NK12 cells died several days (approximately 5 days) before the remainder of the mice in
that group.  This illustrates a fine balance in which the presence of IL-12 and IFNγ leads to
therapeutic effect, however, in this case where IL-12 is present while IFNγ is absent, severe
toxicity is induced.
Thus, it is clear that IFNγ produced by the host rather than by the A-NK cells is critical
for the anti-tumor effect of A-NK12 treatment.
5.4  DISCUSSION
Our work with IL-12 gene transduced A-NK cells has demonstrated a profound effect of IL-12
on the production of IFNγ by both the A-NK cells and the host.  By employing IFNγ KO mice,
we have demonstrated that IFNγ is crucial for the anti-tumor effect mediated by A-NK12 cells
and it became clear that host-derived IFNγ is much more important than the contribution of the
A-NK12 cell-derived IFNγ.  Surprisingly, when both sources were knocked-out for IFNγ
production, all of the mice died within 72 hours of the transfer of A-NK12 cells.  Thus, the
removal of IFNγ from the system actually produced a toxic, lethal environment as witnessed by
fluid build-up in the lungs.
A-NK12 cells generated from WT mice provided a significant survival benefit in tumor-
bearing WT recipient mice, as seen before, compared to A-NKmock.  Since WT tumor-bearing
mice that had received A-NK12 cells from IFNγ KO mice survived as long as those receiving A-
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NK12 cells from WT mice, we can conclude that the contribution of IFNγ from A-NK cells is not
important.  In addition, when WT A-NK12 cells are transferred into IFNγ KO recipient mice the
therapeutic benefit is abrogated, again illustrating a major role of the host in producing IFNγ.
The A-NK12 cells, with their limited presence in vivo following transfer, can probably produce
only a limited amount of IFNγ.  This is apparently sufficient to protect from toxicity but not
benefit therapy.  However, to mediate anti-tumor therapy, i.e. increase animal survival, the A-
NK cell delivered IL-12 is needed to stimulate the host to produce IFNγ.  From the NOD-SCID
experiment and these IFNγ KO experiments, we found that host T and NK cells cannot account
for the IFNγ contribution in anti-tumor therapy.  The abundance of CD11c+ cells in the tumors
could provide a good source of IFNγ.  It has been shown that macrophages229 and neutrophils230
can, in fact, produce IFNγ in response to IL-12 stimulation.  Since host T and NK cells are not
important for the increase in animal survival A-NK12 cells/IFNγ generates, we believe that the
IFNγ, consequently, is acting predominantly back on the host macrophages and/or exogenously
delivered A-NK cells, in mediating anti-tumor therapy.  Thus, despite evidence for T, B, or NK
cells’ lack of direct activity in survival benefits, as seen in NOD-SCID mice, we have established
that the host is indeed mobilized through our A-NK12 therapy, at least through a clear and
instrumental role of IFNγ.
When IFNγ KO mice received A-NK12 cells generated from IFNγ KO mice, all animals
surprisingly died within 48-72 hours.  It is apparent from two separate experiments that as long
as some IFNγ is present in the system (and the tumor microenvironment, presumably), produced
by the host or A-NK cells or both; mice can be rescued from the toxicity induced when IFNγ is
completely absent.   When the donor A-NK12 cells are generated from WT mice, no toxicity is
seen; neither in WT nor IFNγ KO recipients, and the A-NK12 cell treatment significantly extends
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the life of WT mice by a week.  Interestingly, though, one IFNγ KO mouse per experiment
receiving WT A-NK12 cells died several days (approximately 5 days) before the remaining mice
in that group.  While these animals may have died from other reasons, their death may indicate
that the IFNγ produced from the WT A-NK12 cells is in most, but not all, cases sufficient to
inhibit treatment-induced toxicity in the IFNγ KO recipients.
We have seen cytokine induced toxicity in other experiments and could easily attribute
the toxicity seen in the IFNγ KO recipients receiving A-NK12 cells from IFNγ KO mice to the
presence of excess cytokine (especially IL-2).  This is the first time, however, that the removal of
a predominantly stimulatory cytokine resulted in exacerbated toxicity.  It could be that sensitivity
of the host to IL-2 is increased when IFNγ is absent while IL-12 is present.  Carson et al. also
found severe toxicity after systemic treatment along with exogenous IL-2 plus IL-12 treatment,
but they could not provide an explanation for the exact course of this toxicity89.  Another
possibility involves indoleamine 2,3 dioxygenase (IDO), which has been shown to act
suppressively in inhibiting T cell proliferation231, 232.  IDO is induced in DCs233, 234 and
macrophages232 by IFNγ.  Thus, in situations of total IFNγ deficiency, immune cells could
proliferate and/or function uncontrolled.  We did not find any significant difference in the
number of immune cells in tumors from the double KO group compared to other groups, but we
cannot exclude that when IFNγ is missing, and therefore IDO missing as well, there may be a
more severe reaction by the infiltrating immune cells (possibly through TNFα production).
It is important to mention that the tumor burden, in terms of tumor number and density
rather than in size of individual tumors, in both experiments was relatively high.  Thus, any
adverse effect of tumor-infiltrating immune cells probably affect the whole lung, leading to fatal
toxicity.  We speculate that if fewer, but not necessarily smaller tumors are present, more normal
95
lung tissue would be left unaffected by the cytokines produced in the tumors and toxicity may, in
that situation, be less severe.  However, while this may hinder overt toxicity, it still does not
explain why only the double KO mice developed fatal toxicity.
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6.0  DISCUSSION
Immunotherapy of cancers has involved the use of T cells, B cells/antibodies, dendritic cells,
and, to a lesser extent, NK cells.  T cells offer an effector cell that can be directly targeted
towards a specific tumor antigen.  Unfortunately, this same feature may limit their broad
application.  Tumors may down regulate MHC expression, making them less susceptible to T
cell killing, or there may be tumor variants that express antigens not recognized by the
adoptively transferred T cells or lost TAA expression all together.  Antibody treatment has
similar difficulties, along with maintaining a suitable systemic level and ensuring delivery to the
center of tumors.  DC-based immunotherapy can present tumor antigens that have been pulsed
onto the cells as well as providing co-stimulation for T cell activation.  The use of cytokine
therapy benefits a systemic response but can often, therefore, also lead to toxicity.  Cytokine
gene-transduced A-NK cell therapy, however, provides an efficient effector cell which is not
antigen specific and therefore can eliminate T cell resistant tumor cells, and combines with it –
due to the tumor-seeking properties of the A-NK cells - an effective means to localize anti-tumor
cytokine expression specifically within the tumor.
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6.1 IL-12
A goal of this dissertation project was to enhance, or at least maintain, the function of A-NK cell
anti-tumor therapy while reducing the amount of exogenously delivered IL-2 (a necessary, but
potentially toxic, component for A-NK cell trafficking, infiltration, and proliferation in tumors),
via cytokine gene transduction.  Transduction of A-NK cells with IL-12 has provided a superior
benefit to standard A-NK cell therapy.  By itself, as we have shown, it has resulted in significant
survival benefit of A-NK cells in mice receiving far less PEG-IL-2 support than what is needed
to support non-transduced WT A-NK cells.  The A-NK12 cells also provide greater overall
survival of tumor-bearing mice, with as little as one PEG-IL-2 injection, compared to both mice
receiving mock transduced A-NK cells and mice receiving non-transduced A-NK cells supported
with high dose IL-2.  The increase in survival of mice bearing these rapidly growing tumors
reached 10 days in an early, day-3, tumor model and 7 days in a more aggressive day-7 tumor
model.  This could translate into months or years of increased survival in cancer patients (whose
tumors usually grow much slower than murine tumors) without the adverse effects of prolonged
(or continuous) exogenous IL-2 administration.  Thus, the primary goal of this project has been
attained through transduction of A-NK cells with IL-12, mediating greater anti-tumor responses
and requiring significantly less exogenous IL-2 support.  Another goal, namely to deliver
cytokines to the tumor microenvironment to stimulate host anti-tumor responses, has also been
established.
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6.1.1 IL-12 works through IFNγ
 IL-12 acting on A-NK cells, and the host as well, could be through a number of
functions.  First, IL-12 may be increasing the A-NK cell lytic function.  Although we did not see
this clearly in cytotoxicity assays with A-NK12 cells, we cannot exclude the possibility that this is
occurring in the more vibrant tumor microenvironment.  Likewise, the IL-12 may be stimulating
endogenous immune cells to be more efficient killers.  Second, IL-12 may simply be maintaining
A-NK cell survival in low amounts of IL-2 through the upregulation of CD25.  It would be
imagined that a longer presence of efficient killers would produce a greater therapeutic outcome.
Finally, as established in Chapter 5, IL-12 is important for its induction of IFNγ.  IL-12, formerly
known as natural killer cell stimulatory factor, has demonstrated a remarkable downstream effect
in the production of IFNγ.  We have shown host IFNγ to be integral, whereas IFNγ produced by
the A-NK cells themselves does not seem to play as significant a role for the efficacy of the A-
NK cell treatment, but surprisingly very important for preventing treatment-induced toxicity.
We have found that the host is critical for the production of IFNγ.  IFNγ may be important, as
described above, for its antiangiogenic function.  With IFNγ removed from the system, tumors in
the lungs could develop new vasculature, supporting their growth.  It has been established,
however, that in the B16 lung tumor model, the B16 tumors are not heavily dependent on
neovascularization235.  The contribution of IFNγ, therefore, is not likely due to its antiangiogenic
capacity.    Further studies using IFNγR KO mice will be needed in order to determine which
component(s) is/are responding to the IFNγ, leading to tumor growth inhibition.
It could be argued that if IFNγ is so important for treatment effect when the host provides
it, how could there be an equally efficient therapeutic effect in NOD-SCID mice receiving A-
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NK12 cells when the primary producers of IFNγ, namely T and NK cells, are absent.  Puddu et al.
has demonstrated an ability of macrophages to produce IFNγ following IL-12 stimulation229,
while Munder et al. have shown similar results with IL-12 and IL-18 stimulation236.  In addition,
it has been shown that human neutrophils can be induced to produce IFNγ upon IL-12
stimulation230.  Thus, these findings clearly establish the potential for other cells present in NOD-
SCID mice to act as a viable source of IFNγ.  We have attempted to measure the production of
IFNγ in NOD-SCID mice, as well as WT mice, that have received A-NK12 cells.  Unfortunately,
no IFNγ could be found in serum obtained 72 hours after adoptive transfer, at least not at the
level of detection (calculated to be ~300pg/ml).  This may be explained by the fact that tumors
were not induced in the mice used in this experiment.  It appears that the A-NK cells will not
persist and reach high enough numbers without tumors to accumulate in.  The IL-12 expressed
by A-NK12 cells will, therefore, not reach levels to stimulate macrophages to produce detectable
IFNγ in the serum.
6.1.2 IL-12 does not induce host cellular immunity
We have shown the host to be important to the anti-tumor responses generated with A-
NK12 cells through its production of IFNγ.  This demonstrates that we, via the cytokine-
transduced A-NK cells, are able to “communicate” with the host immune system to generate
anti-tumor reactivity.  We wondered, however, why we could not observe the induction of long-
term adaptive cellular immunity despite the presence of pro-inflammatory cytokines and A-NK
cells in the tumor microenvironment.  If cytokine gene transduced A-NK cells are capable of
activating specific T cell responses there may be a number of reasons why this, in our
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experiments, did not manifest itself in terms of survival benefits.  An obvious reason,
considering survivability readouts, could have to do with the time that is needed for the efferent
arm of adaptive responses to be mobilized.  It would take 4 or 5 days from the time that antigen
is taken up, presented to antigen specific T cells, T cell expansion, and T cell traffic back to the
site of insult.   Considering this time period, the growth kinetics of the tumor may exceed the
ability of a well-armed immune response to overcome it.  By the time effector cells arrive at the
tumor, the challenge may be insurmountable.  However, even in an experiment involving a day-3
lung tumor model and another involving a lower B16 cell inoculum, giving more time for T cells
to expand to critical numbers than in the more advanced day-7 tumor model, mice did not
generate long-term adaptive immunity.  This indicates that there could be more inherent
problems with the efferent arm of the immune response, i.e. antigen specific T cells may
proliferate but not be fully armed or may have been rendered anergic, have difficulty in
trafficking back to the antigenic source (tumor), or be impeded by regulatory or suppressive
factors.
A second possibility involves a more fundamental problem with the afferent arm, such
that the efferent arm would not be properly activated.  This could be due to an inability of
immature DCs to traffic to lung metastases, become matured in response to appropriate stimuli,
or traffic back to secondary lymphoid tissue for T cell priming.  We do not feel there is an
inadequacy of immature DC trafficking into the tumors, as we have found relatively high
densities of CD11c+ cells within tumors, regardless of whether the animals had received any
treatment or not.  Although we are not certain that these CD11c+ cell are in fact DCs and not
macrophages, given their high expression of CD11c, we do believe that DCs are present to some
degree.  Most of the CD11c+ cells are filled with phagocytosed melanin, clearly demonstrating
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their ability to take up tumor cell debris.  In spite of what we perceive as a suitable DC
maturation environment, i.e. an abundance of cytokines such as IL-2 (injected) and IL-12 (from
the transduced A-NK cells), liberation of tumor antigen(s) due to tumor cell killing by the A-NK
cells, and the possibility for cross-talk between NK and DC, there is less evidence to support the
idea that DCs, if they are present, are actually matured appropriately.  Thus, an inability of
matured DCs to traffic to lymph nodes remains a possibility for a defect in the afferent arm.  This
is quite conceivable considering that the lymph nodes draining the lungs are more involved with
airborne antigens, while in B16 metastases that are established “deeper” in the lung parenchyma
where there may be fewer antigen presenting cells available, unlike at the air/lung interface.  It is
possible that the intratumoral CD11c+ cells are efficient in acting as antigen presenting cells.
Even if they are genuine DCs, there may be insufficient lymph vessels in the tumors to secure a
functional path for the DCs by which they can reach the draining LNs.  A lack of proliferation of
antigen specific T cells in the draining lymph nodes following A-NK cell treatment could point
to any of these deficiencies in the afferent arm.
By looking in the draining lymph nodes of the lungs (i.e. the mediastinal lymph nodes),
we could get a better idea if there are defects in the afferent or efferent arm of the immune
response, or, in other words, if early events in effector cell induction/priming (i.e. T cell
proliferation) in fact is taking place following A-NK cell treatments.  We supplied the system
with both a T cell that recognizes a specific antigen and a tumor that will express it with the OT-
I/MO5 model.  By doing so, we are starting with a greater T cell pool that can become activated,
providing a greater window of opportunity to observe T cell responses (in a shorter amount of
time).  The MO5/OT-I offers the B16 tumor cell line that stably expresses ovalbumin and the
ovalbumin transgenic, MHC-I restricted (OT-I) CD8+ T cell, which recognizes the OVA-derived
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peptide, SIINFEKL. We decided to investigate the ability of A-NK12 to promote T cell
proliferation, and how the addition of TNFα gene-transduction of the A-NK cells might affect
this process.  We also tested A-NK12 cells transduced with CD40L.  Interacting with CD40 on
DCs, CD40L can act to mature DCs237, 238.  Considering a lack of long-term response from A-
NK12 and A-NK12/TNFα, we hypothesized that CD40L stimulation of antigen presenting cells, e.g.
DCs, would initiate T cell responses that IL-12 or IL-12/TNFα  may not mediate.
Disappointingly, we did not observe any signs of OT-I proliferation in the draining LNs,
indicating a lack of proper stimulation of the afferent arm of the adaptive immune response
following cytokine-gene transduced A-NK cell treatment.  It could be argued that CD8+ T cells
need CD4+ T cell help to proliferate efficiently.  We included OT-II (ovalbumin-specific CD4+
T cells) to a couple of the experiments without noticeable effects on OT-I or OT-II proliferation.
In case DCs traffic from the lungs parenchyma more readily through the bloodstream rather than
the lung lymphatics we investigated the possibility of systemic activation by looking for OT-I
cell proliferation in the spleen.  We found no increase in OT-I cell proliferation at this site in any
experiments.
Since we did not observe any changes in OT-I cell numbers in mediastinal lymph nodes
or spleens of mice receiving A-NK12 or A-NK12/TNFα treatment, we set up an experiment in which
transduced A-NK and MO5 tumor cells were mixed and injected subcutaneously to initiate
responses in inguinial lymph nodes.  This is a more widely used model that, along with the
incorporation of adjuvant and ovalbumin protein as a positive control, should provide a means to
observe T cell proliferation if this technique is successful.  We found that only the positive
control group, consisting of Freund’s adjuvant and ovalbumin protein, was successful in
promoting OT-I cell proliferation in the inguinial lymph nodes.  Adjuvant alone and each of the
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transduced cell/MO5 treatments (including IL-12/TNFα and IL-12/CD40L) could not initiate T
cell proliferation.  This again indicates that the A-NK cell mediated killing of tumor cells, even
in an environment containing IL-12, in conjunction with TNFα or CD40L, is not sufficient to
stimulate T cell proliferation.  CD40L may be a good candidate for activating DCs but it may be
more effective when present in the lymph nodes rather than in the lung tumors (where transduced
A-NK cells are expressing it).  Therefore, there is a need to identify alternative cytokines and
chemokines and amounts of them that, when delivered by A-NK cells, will stimulate the afferent
arm of adaptive immunity and the proliferation of antigen specific T cells.
6.1.3 Concerns with IL-12 application
Interestingly, it has been shown that IL-12 may decrease the early CTL activity in mice
when given as adjuvant.  It plays a more extensive role following this period of suppression239.
Ribas et al. demonstrated a detrimental effect of chronic therapy involving IL-12 administration
in which anti-tumor reactivity was suppressed240.  On the other hand, Kilinc et al. demonstrated
reductions of FoxP3+ Treg cells, along with increases in CD8+ effector T cells, in tumors with
the intratumoral injection of IL-12, illustrating the usefulness of IL-12241.  In addition, A-NK12
cells produce significant amounts of IL-10 which clearly could suppress T cell responses.  The
conflicting immunostimulatory and immunosuppressive results obtained with IL-12 point to
great impact of the model, timing, dosage, and delivery method.  Clearly, IL-12 does not, in our
system, contribute much to the host’s T, B, or NK cell effector responsiveness, as these effector
cells did not seem to be important when we investigated them in WT vs. NOD-SCID tumor-
bearing mice.  If IL-12 is acting to suppress host T cells this may explain, in part, why we cannot
see long-term immunity being generated in WT mice either.  However, even with possible
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suppression of host T cells occurring, the A-NK cells can still respond to the IL-12 being
produced, along with downstream IFNγ produced by the host.  In our model, A-NK12 cells reach
the tumors where they produce IL-12, and destroy tumor cells without the need of a high and
constant supply of IL-2, due to the presence of the IL-12 (leading to CD25 upregulation).  As the
A-NK cells die off, the IL-12 levels will also drop and may soon reach levels unable to maintain
any host response that may be developing.  Thus, before the CTL responses are fully developed,
the presence of IL-12 within the tumors/draining LNs may have diminished to suboptimal levels.
The argument would then be to continue or repeat the injections of A-NK12 cells to overcome
this lag period.  While we, in one experiment where two A-NK12 injections were given 4-days
apart, did not see any increase in therapeutic efficacy or signs of a further developed adaptive
host immune response, it is still very likely that with the right timing, serial injections of
transduced A-NK cells may support the initiation of adaptive anti-tumor responses.
In addition to the potential lag period, we have, as mentioned above, found a dramatic
production of IL-10 by IL-12 transduced A-NK cells.  Others have demonstrated this with
human NK cells following IL-2 and/or IL-12 stimulation242.  It is possible that a lack of host anti-
tumor immunity could be explained by the A-NK cells’ ability to produce IL-10.  Most widely
known for its effects in Th2 immunity, IL-10 could be a key target in dampening potential IL-12-
mediated host immunity, possibly by preventing the accumulation of DCs in tumors243.  It may
also prevent T cell stimulation by impairing antigen cross presentation by DCs244.  Along with
TGFβ, IL-10 is used by Tregs to act immunosuppressively245.  In contrast, IL-10 has been
shown, to act as an NK cell stimulator246, 247.  IL-10 has been used extensively, with success, in
animal tumor models248-251 and, in at least one instance, found to be associated with better
prognosis in human tumor, a leukemia, B-CLL252.  More prominently, the expression of IL-12
105
and IL-10 together, by transduced tumor cells, synergizes to mediate anti-tumor immunity
against subcutaneous and lung tumors253.  Additional experiments (e.g. KO mice or cytokine
depletions) are needed, therefore, to determine the role of IL-10 as a stimulator or suppressor in
this model.
6.2 IL-2
6.2.1 IL-2 transduction to support A-NK cells
In spite of a number of attempts with different IL-2 gene containing adenoviral vectors,
we have not been completely successful in transducing A-NK cells to become totally
independent of exogenous IL-2.  We do not believe, however, that IL-2 gene transduction is
completely unsuccessful altogether.  Instead, it is more likely a matter of insufficient amounts
being produced.  According to our calculations, the amount of IL-2 required for maintaining A-
NK cells in vitro would be in the range of 30-300ng/x106 cells/ml which is 50 to 500-fold more
than what we have obtained with IL-2 transduction thus far.  The objective then became a matter
of how a more suitable, diminished presence of IL-2, either exogenously delivered or transgene
expressed, could suffice in maintaining A-NK cell survival and functionality.  One possibility
that has provided favorable results combines IL-2 transduction with IL-12 transduction.  In an
experiment in which A-NK cells were co-transduced to express both IL-12 and IL-2, mice
receiving A-NK12/2 cells were capable of preserving the ~7-day increase in survival (median 28
days compared to 21.5 for A-NKmock, p value=0.0005).  Remarkably, this has been accomplished
without any support from exogenous PEG-IL-2.  These results were consistent with treatment
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with A-NK12 cells plus one injection of PEG-IL-2 given at time of the A-NK cell injection.  (30
days with A-NK12 and 28 days with A-NK12/2, p value=0.3916).  Thus, when coupled with the
high production of IL-12, the modest IL-2 production by IL-2/12 transduced A-NK cells
apparently was capable of maintaining viability and function of the A-NK cells and thereby
completely eliminating the need for exogenous IL-2 support.
6.2.2 Concerns with IL-2 application
IL-2 needs to be carefully considered in its application.  Most important, if too much IL-2
is produced, toxicity may occur.  As stated, however, with the low amounts of IL-2 produced by
our transduced A-NK cells, this is not likely to be a concern.  Nevertheless, as intratumoral IL-2
allows for the survival and proliferation of effector T cells, it produces similar effects in T
regulatory cells as well.  How much of a factor Tregs play in preventing long-term immunity
toward the tumor needs further investigation in this model system (i.e. via Treg depletions).
Nagai et al. demonstrated greater therapeutic benefit of IL-12 when it was combined with
CD4+CD25+ T cell depletions254.  We have tested for the presence of FoxP3+ T regulatory cells
in the B16 lung tumors following different cytokine-gene transduced A-NK cell treatments and
found that FoxP3+ cells are present in the lung sections.  The levels of these cells were
unaffected with A-NK12 cell treatment compared to untreated mice.  We found, however, a slight
decrease in the presence of Tregs following A-NK12/TNFα cell treatment.  We are not certain if
this slight difference between treatment groups is functionally important or whether the levels of
Tregs found in the tumors are able to prevent the successful induction and implementation of
adaptive host immunity.  We do believe, however, that the influence of Tregs on the therapeutic
efficacy of the A-NK12  treatment should be taken into account in the future.
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6.3 FUTURE APPLICATION OF CYTOKINE GENE-TRANSDUCED A-NK CELLS
We have shown here that transduced A-NK cells can be a powerful anti-tumor tool by delivering
the right combinations of cytokines, and possibly in the future, chemokines and/or danger signals
also.  Determining which agents should be delivered and to what extent will continue to become
a major focus in this lab.  It may be a matter of providing additional injections of transduced A-
NK cells.  As described above, the presence of a cytokine (or any other agent) delivered by A-
NK cells may not persist long enough to continue to promote immunity if it even has been
initiated.  Therefore, multiple injections of transduced A-NK cells could supply these agents at
critical time points to boost levels that have diminished.
It may be that the initiation of an effective immune response requires injections of A-NK
cells delivering various cytokines at different time points in the development of the response.
This may be an important consideration for coordinating the immunologic processes by way of
key regulators.  For example, the first dose of A-NK cells might need to be transduced with A-
NK cell promoting factors that maintain their survival and cytolytic function such as IL-12,
which has been thoroughly tested in this project.  However, the addition of other cytokines (such
as GM-CSF, IL-2 or IL-15) and chemokines, that can draw immune cells into the tumors, will
establish an appropriate immune cell population consisting of both innate effector cells and
antigen presenting cells.  Once this has happened, a second dose of A-NK cells, this time
delivering cytokines involved in generating adaptive immunity (i.e. IL-12, TNFα, CD40L), may
secure initiation of a Th1-biased T cell response.  In addition, removing regulatory cells or
immunosuppressive cytokines followed by the delivery of danger signals (e.g. TLR ligands such
as CpGs) that can trigger immune activation against the tumor, should further stimulate T cell
priming.
108
We feel that what has been accomplished through this dissertation work, albeit without
the induction of long-term adaptive immune reactivity, remains a remarkable finding in that A-
NK12 cells consistently provide significant anti-tumor therapy, with both the A-NK cells and host
playing a vital part.  Importantly, the application of A-NK12 cells has lead to a reduction in
exogenous IL-2 support, and a subsequent elimination of IL-2-induced toxicity.  Thus, we are
confident that with the right combination of additional cytokines and proper treatment timings,
even greater anti-tumor responses can be generated from the advances we have already made
based on the A-NK12 cells.
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